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On the Involvement of the Low-Density Lipoprotein Receptor in the
Pathogenesis and Progression of Alzheimer’s Disease

Jose Francisco Abisambra Socarras

ABSTRACT

Alzheimer’s disease (AD) is the most prevalent form of ageassociated dementia. Cholesterol dysregulation is linked with AD onset.
Besides age, the most important risk factor associated with AD is the
inheritance of the ε-4 allele of apolipoprotein E, a cholesterol transporter.
In addition, while hypercholesterolemia has been shown to be an
independent risk factor for AD, the nature of the cholesterol-AD link is
still not clear. This gap in our understanding is partly due to a lack of
knowledge about cholesterol metabolism in the central nervous system
(CNS).

The low-density lipoprotein receptor (LDLR) is the main receptor of
apoE and a central regulator of serum cholesterol levels. Therefore, we
vi

sought to characterize the potential participation of LDLR in AD
pathogenesis and/or progression. Previous reports with similar aims came
to contradictory conclusions. Such studies assessed potential changes in
AD in the absence of LDLR by utilizing the LDLR-/- mouse model and
crossing it to AD mouse models.

Initially we evaluated LDLR-/- mice as a suitable model to study AD.
We found that LDLR-/- mice overexpressed a functional splice-variant of
LDLR, LDLR∆4. Moreover, its protein localized in similar regions as the
LDLR did in control mice. Finally, we determined that LDLR∆4 bound
apoE, which underscores the impact of the isoform’s function in the CNS.

We then focused on characterizing changes to LDLR in AD models.
We found that APP overexpression in cells increased LDLR mRNA and
protein. APP overexpression and Aβ treatment shifted LDLR localization.
An AD mouse model showed increased LDLR in hippocampus. Conversely,
LDLR levels were decreased in APP-/- mice. Finally, we found that
microtubules were affected in cells overexpressing APP.

In conclusion, the data presented argue for the importance of LDLRmediated regulation of cholesterol during AD progression. Also, LDLR may
vii

participate in the initial pathogenic insults leading to amyloid deposition,
which make it a potential therapeutic target to treat AD. Finally, we
propose that APP/Aβ overexpression disrupts microtubule formation; this
alteration affects protein trafficking. One of the proteins affected is LDLR,
the repercussions of which may ultimately result in cholesterol
dysregulation.

viii

NANOS GIGANTIUM HUMERUS INSIDENTES
(Dwarves standing on the shoulders of giants)
-Bernard de Chartres

Scientific progress cannot be achieved without the strong
foundation edified by other scientists. It is from the past that aspiring
scientists like myself find inspiration to formulate our own hypotheses.
The work in this dissertation is inspired by elegant reports written by
scientists who exercised ingenuity, rigorous methodology, and astute
interpretation in the fields of heart disease and Alzheimer’s disease.
These two devastating diseases have marred the lives of millions
throughout the world. Thusly, the research of these ailments demands
the intensity and perseverance these giants have dedicated.

In 1901, while director of the state asylum of Frankfurt am Main,
the psychiatrist and neuropathologist Alois Alzheimer met and treated
Auguste D. She had been referred to the asylum for suffering from
behavioral disorders characterized by progressive memory loss, irritation,
and disorientation. After her death in 1905, Alzheimer performed an

autopsy and described in 1906 the major hallmarks of the disease that
today bears his name: neurodegeneration, amyloid plaques, and
neurofibrillary tangles. This description is still used today to confirm
Alzheimer’s disease diagnoses, underscoring the importance of Alois
Alzheimer’s discovery.

While investigating the root causes of familial hypercholesterolemia
(FH), Michael Brown and Joseph Goldstein discovered the low-density
lipoprotein receptor (LDLR), the main protein responsible for removing
LDL cholesterol from the blood torrent. They concurrently described what
is known today as the LDLR pathway, which includes a general step in the
import of substances inside cells termed receptor-mediated endocytosis.

Brown and Goldstein’s astute strategy was to analyze the genetic
makeup of individuals from families who suffered from high serum
cholesterol levels. They found mutations in the LDLR gene that rendered
the receptor unable to function in separate steps of its metabolic cycle.
As a result, the patients’ ability to remove LDL from the blood was
impaired, leading to hypercholesterolemia and subsequent sequelae.

Brown and Goldstein were awarded the Nobel Prize in Physiology or
2

Medicine in 1985 for these discoveries. Their strategy is used in the
research of other diseases including AD, and has revealed important
mutations that are involved in the disease process. The mutant forms of
several human genes that cause or promote familial Alzheimer’s disease
have been introduced into the genome of transgenic mice, which serve
today as the most common in vivo model for AD research.

Without exception, I based the hypotheses and methods contained
in this dissertation on the findings of many other researchers. I’ve had
the unique opportunity to be a scientist during a very exciting time. The
resources available today added to our own intellectual efforts produced
the results presented in this dissertation. The experimental design and
data presentation contain the signature of our own ingenuity to reveal
the results presented herein. Conclusions derived from these results
required careful analysis. This is our contribution. I hope that our results
will feed the body of knowledge upon which other scientists will discover
relevant information that may lead to strategies and approaches targeted
to reduce or eliminate the suffering caused by AD.

3

INTRODUCTION

Alzheimer’s Disease

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder
and the most common cause of dementia (Schoenberg, Kokmen, &
Okazaki, 1987). AD patients are characterized by a loss of or decrease in
memory, which is accompanied by a decline in at least one of the
following cognitive abilities: (1) generation of coherent speech as well as
understanding written language; (2) identification of objects; (3)
execution of motor tasks; and (4) capability to form abstract thought,
make sound judgment, and plan and carry out complex tasks
(Association, 2008). To meet these criteria, the patient must have intact
motor and sensory systems, and must understand the tasks he or she is
asked to perform.

According to the Alzheimer’s Association’s 2008 Alzheimer’s Disease
Facts and Figures report, 5.2 million people in the United States suffer
from AD, and it accounts for 70% of dementias in people age 71 or older.
4

Furthermore, 50% of the population over 85 years of age suffers from
AD.

Onset of AD after age 65 is defined as late-onset or sporadic AD,
which accounts for over 95% of the AD population and has an idiopathic
etiology with some genetic contribution. Early-onset AD, which
constitutes less than 1% of the remaining AD population, has a wellcharacterized genetic etiology, whereby specific mutations lead to
autosomal dominant inheritance of ‘familial’ AD, and it typically ensues
under the age of 65. Epidemiological studies show that AD is more
prevalent in women, in people who have fewer years of education, and in
African Americans.

Despite its first description over one hundred years ago, there is
still no cure for AD. However, reports that AD patients have severely
reduced levels of acetylcholine (Ach), a key memory-associated
neurotransmitter,

triggered

the

development

of

pharmacological

approaches to modulate Ach (Bartus, Dean, Beer, & Lippa, 1982; Coyle,
Price, & DeLong, 1983; Davies & Verth, 1977; Gaykema, et al., 1992).
Pharmacological modulation of acetylcholine transmission would be
expected to diminish the decline in learning and memory. In fact, it has
5

been reported that there is mild cognitive improvement (Giacobini,
1997). One approach is to reduce or inhibit acetyl cholinesterase (AchE)
activity, which increase Ach levels and aid in improving learning and
memory. Unfortunately, cognitive improvements are only mild due to
short half-life and adverse side effects, which restrict their use (Forsyth,
et al., 1989; Tariot, et al., 2000; Watkins, Zimmerman, Knapp, Gracon, &
Lewis, 1994). Donepezil hydrochloride (Aricept) has been the most
effective AchE inhibitor and is commonly used to treat AD patients
(Rogers, Doody, Mohs, & Friedhoff, 1998).

Cardiovascular disease and AD share many risk factors and
correlates (Reid, Urano, Kodama, & Hamakubo, 2007), such as
hypercholesterolemia (Soneira & Scott, 1996) and atherosclerosis
(Hofman, et al., 1997; Kalback, et al., 2004; Reid, et al., 2007),
hypertension (Skoog, et al., 1996), and diabetes type 2 (Ott, et al.,
1996). Consequently, statins, cholesterol-lowering drugs, have been
evaluated as therapeutic agents to treat AD. However, so far the results
are inconclusive (Dufouil, et al., 2005; Rea, et al., 2005; Sjogren, et al.,
2003; Sparks, Connor, Browne, Lopez, & Sabbagh, 2002; Sparks,
Martins, & Martin, 2002; Wolozin, Kellman, Ruosseau, Celesia, & Siegel,
2000; Zamrini, McGwin, & Roseman, 2004; Zandi, et al., 2005).
6

The Mini Mental-State Exam (MMSE) is used to evaluate subjects
who begin to present symptoms of cognitive impairment. During the past
few years, I had the opportunity volunteer at the Johnnie B. Byrd, Sr.
Alzheimer’s Center and Research Institute Clinic to evaluate the cognitive
status of Spanish-speaking individuals using the MMSE. I found that in
the initial stages of cognitive decline patients often present emotional
distress in the form of depression, frustration, and irritability. These signs
further exacerbate symptoms of dementia due to ensuing apathy, which
leads to hypoprosexia or loss of attention. Patients in advanced stages of
AD or other types of dementia are typically apathetic. It was in these
cases where it became evident that the caregivers were the burdened
victims.

Inasmuch as the disease causes harm to patients, social and
economic burdens are intimately related. Direct and indirect costs of the
disease in the US have risen to over $148 billion annually. This figure
does not account for an estimated $89 billion provided by the 10 million
caregivers in unpaid services to AD patients (Association, 2008). This
fiscal hemorrhage burdens State and Federal economies. The urgency for
the discovery of effective therapeutic interventions is increasing as “baby
boomers” reach the age of AD onset, which is estimated to amount to 10
7

million people over the upcoming decades (Association, 2008). By 2050,
it is estimated that the incidence of AD will reach one million persons per
year and a prevalence of 11 to 16 million. Therefore, these costs are
likely to widen the hole in the U.S. healthcare system as well as debilitate
the efforts in place for the current economic recovery.

8

Alzheimer’s Disease Pathology

The Clinical signs of Alzheimer dementia are the result of
neurodegeneration, which is rooted in the build up of extracellular
amyloid or senile plaques and intracellular neurofibrillary or tau tangles
(Kidd, 1963). Alois Alzheimer recognized these structures in the brain
sections of Auguste D. Plaques and tangles are similar in that they are
aggregated protein complexes that deposit due to their highly
unstructured and hydrophobic nature. However, they differ in their
proteinaceous components and the pathways through which they
conglomerate.

The etiological hypotheses of AD pathogenesis have divided the
field into two groups that have been jocularly named “Tau-ists” and
“βAPP-tists” (Tanzi & Parson, 2000). The former contend that the seeding
pathogenic insult is the formation of tangles. Part of the argument is
rooted in the fact that the amount of tangles directly correlates with the
degree of dementia (Alafuzoff, Iqbal, Friden, Adolfsson, & Winblad,
1987), which is not true of amyloid plaques. The βAPP-tists make
9

compelling arguments based on the findings that mutations in the genes
coding for amyloid precursor protein (APP) (Ancolio, et al., 1999;
Chartier-Harlin, et al., 1991; Eckman, et al., 1997; Goate, et al., 1991;
Hendriks, et al., 1992; Mullan, et al., 1992; Murrell, Farlow, Ghetti, &
Benson, 1991) and presenilin (Levy-Lahad, et al., 1995; Rogaev, et al.,
1995; Sherrington, et al., 1995) have been identified in patients with
familial AD. Also, there is an APP gene-dosage effect leading to AD or ADlike symptoms in Down’s syndrome (DS) individuals, who eventually will
suffer from AD after their fourth decade of life (Rumble, et al., 1989; K.
E. Wisniewski, Wisniewski, & Wen, 1985). Since the APP gene is in
chromosome 21, DS individuals carry an extra copy of this gene, thereby
increasing the amount of APP. Although recent evidence indicates that
plaque deposition antecedes tangle formation (Gotz, Chen, van Dorpe, &
Nitsch, 2001; J. Lewis, et al., 2001), it is not yet clear whether
treatments would be most effective by targeting the clearance of plaques
or tangles and when during the course of the disease, such treatments
should be initiated.

The most popular hypothesis of AD pathogenesis is known as the
amyloid cascade, which states that Aβ generation is the initial pathogenic
step leading to neurodegeneration and dementia (Hardy & Higgins,
10

1992). Experimental evidence in transgenic mouse models indicates that
Aβ deposition is antecedent to tangle formation. Alternative hypotheses
propose pacifying theories contending, for instance, that both hallmarks
are the result of similar pathogenic pathways or that plaques and tangles
are not the major pathogenic culprits in AD but rather by-products of a
more upstream insult to the CNS that accumulates over time.

11

Amyloid Precursor Protein

Amyloid deposits at the center of senile plaques are the result of
abnormal processing of the amyloid precursor protein (APP) (Kang, et al.,
1987). In this process, APP is coordinately cleaved by two enzymes, βand γ-secretase. In this amyloidogenic pathway, the APP protein
generates a 38-42 amino acid peptide termed Aβ. The most toxic peptide
product is Aβ42, and it is capable of self-aggregation into oligomers of
varying lengths including fibrils (Lambert, et al., 1998). The β-pleated
sheet structure of this peptide makes it more prone for aggregation.

Other

proteins

can

catalyze

Aβ

aggregation.

Non-classical

chaperones, like apolipoprotein E (apoE) (Costa, Nilsson, Bales, Paul, &
Potter, 2004; Howland, et al., 1998) and anti-chymotrypsin (ACT)
(Abraham, Selkoe, & Potter, 1988), bind Aβ and are thought to promote
its deposition into amyloid. However, the notion that plaques are
responsible

of

neurotoxicity

is

currently

being

reevaluated.

Overwhelming data indicate that it is not plaques that cause the
12

pathogenic insult leading to AD, but rather the Aβ oligomers themselves
that induce neurodegeneration (Hartley, et al., 1999; Hsia, et al., 1999;
Lambert, et al., 1998; Lemere, et al., 1996; Mucke, et al., 2000; Walsh,
et al., 2002).

The APP gene is located on chromosome 21q21.2-3, and it codes
for three major isoforms of 770, 751, and 695 amino acids (Kitaguchi,
Takahashi, Tokushima, Shiojiri, & Ito, 1988). APP695 lacks a 56-residue
Kunitz protease inhibitor sequence that is present in the other two
isoforms. Furthermore, APP770 has a 19 amino acid sequence of unknown
function that is absent in APP751. Although the three isoforms can be
made in many tissues and cells, the comparative ratios with which they
are generated are different according to the type of tissue or sub-region
within the tissue, and the special circumstances under which the tissue is
stimulated, such as specific developmental stages or disease. For
instance, the brain mainly favors expression of APP695 (Tanaka, et al.,
1988), but cultured human astrocytes and hippocampal rat astrocytes
preferentially make APP770 and APP751 (Gray & Patel, 1993; Rohan de
Silva, et al., 1997). So far, there is no definitive explanation for these
differences.
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APP is found in many membrane-associated structures in the cell,
and it can be processed in more than one location. Notably, APP has been
detected in the endoplasmic reticulum (Tomimoto, Akiguchi, Wakita,
Nakamura, & Kimura, 1995), several Golgi compartments (Caporaso, et
al., 1994; Tomimoto, et al., 1995), the cell membrane (Tomimoto, et al.,
1995), and lysosomes (Haass, Koo, Mellon, Hung, & Selkoe, 1992).
Furthermore, APP deposits have been observed to be associated with
specific molecules in synaptic vesicles, in postsynaptic membranes of
axons and dendrites (Schubert, et al., 1991; Shigematsu, McGeer, &
McGeer, 1992), and coupled to membrane rafts (Bouillot, Prochiantz,
Rougon, & Allinquant, 1996; Hayashi, Mizuno, Michikawa, Haass, &
Yanagisawa, 2000).

A great deal of research is devoted to characterizing the normal
function of APP as a means to understand the pathogenesis of AD. APP
has been shown to assume the role of a G-protein-coupled receptor due
to its intracellular association with G0 in in vitro experiments (Brouillet, et
al., 1999). Also, many APP-binding partners participate in cell adhesion
and motility, which suggests that APP is also involved in these processes
(Breen, 1992; M. Chen & Yankner, 1991; Sabo, Ikin, Buxbaum, &
Greengard, 2001). However, the physiological function of APP and its
14

cleavage products is still poorly understood. Conversely, a lot is known
about APP’s breakdown product Aβ, due to its participation in Alzheimer’s.
AD pathogenesis is the result of increased levels of Aβ42, which in FAD
can be due to mutations on the genes coding for APP and/or the enzymes
that process APP. These enzymes have been termed secretases as the
products of their proteolytic activity are secreted, and they have been
catalogued based on the target site on APP, namely α-, β-, and γsecretases.

15

α-secretase

APP cleavage can undergo non-amyloidogenic processing, whereby
α-secretase cleaves within the Aβ sequence (termed the α-site),
hampering formation and subsequent release of the fully formed toxic Aβ
peptide. The resulting product is a soluble species named sAPPα, which
corresponds to the large ectodomain of APP. Normally, this is the main
product of APP processing in the body (Hooper, 2005); however, in AD
patients, sAPPα is significantly decreased in cerebro-spinal fluid (CSF)
(Lannfelt, Basun, Wahlund, Rowe, & Wagner, 1995; Van Nostrand, et al.,
1992). The α-secretase activity is dependent upon the distance of the
cleavage site to the membrane, and the secondary helix structure
(Sisodia, 1992). Both of these conditions can be altered by FAD
mutations.

Protein kinase C (PKC) activators and metabotropic glutamate
receptor agonists induce cleavage of APP at the α-site (Kirazov, Loffler,
Schliebs, & Bigl, 1997; Nitsch, Deng, Wurtman, & Growdon, 1997). Since
16

these stimuli activate a large number of enzymes, it has been suggested
that APP is not the only substrate for an α-secretase. Instead, three
enzyme candidates may in fact be α-secretase (Hooper, 2005): tumor
necrosis factor-α converting enzyme (TACE/ADAM17) (Black, et al.,
1997; Moss, et al., 1997), ADAM9, and ADAM10 (reviewed in (Allinson,
Parkin, Turner, & Hooper, 2003)). Nonetheless, there is no confirmation
of these findings. Promotion of α-cleavage on APP is an attractive
therapeutic goal currently underway. However, this requires development
of specific α-secretase agonists, since substances like PKC activators have
wide-range targets.

17

β-secretase

Pathogenic, Aβ-forming pathway of APP processing is executed by
β- and γ-secretases’ cleavage at the amino and carboxy-termini of the Aβ
peptide, respectively. There are two homologue β-secretases, BACE1
(Vassar, et al., 1999; Yan, et al., 1999) and BACE2 (Farzan, Schnitzler,
Vasilieva, Leung, & Choe, 2000) (β-site APP-cleaving enzymes), and they
are membrane-bound, aspartyl proteases that target APP. Their location,
expression, and activity differ (Bennett, et al., 2000). BACE1 is found in
many tissues, however particularly in brain and pancreas. In the CNS,
BACE1 is mainly produced in neurons, while very low levels are
detectable in glia (Vassar, et al., 1999). These data correlate with
functional studies that show elevated products of BACE1-specific activity
on APP in cortical neurons (Sinha, et al., 1999). On the contrary, BACE2
expression in the brain is notably lower than in peripheral tissues such as
colon, stomach, and thyroid gland (Bennett, et al., 2000). In the CNS,
BACE2 mRNA levels are virtually undetectable except in neurons of the
ventromedial hypothalamus and the mamillary body (Bennett, et al.,
18

2000). BACE2 activity is less prevalent than the pathogenic BACE1
cleavage, which takes place at the amino terminus of Aβ and renders a
soluble and extracellular fragment of APP, sAPPβ.

The product of BACE1 processing of APP is a membrane-bound
carboxy-terminal fragment, APP-CTFβ, which is then available for γsecretase to cleave at the carboxy-terminus of Aβ. This toxic peptide is
then released. In contrast, BACE2 cleaves at the β-site in a nonamyloidogenic manner within the Aβ peptide sequence. Therefore, Aβ
generation is hampered (Farzan, et al., 2000). Therapeutic interventions
to increase BACE2’s activity on the non-pathogenic target on APP are
currently underway (Farzan, et al., 2000).

Like in the case of α-secretase, full-length APP is not the only
substrate for β-secretases (Liu, Doms, & Lee, 2002). Nevertheless,
BACE1’s pathogenic processing of APP is increased in AD patients where
its levels and activity are elevated. This risk is particularly high in
individuals carrying the Swedish mutation because BACE1 can cleave
APPSw with significantly greater specificity than alternate forms of APP
(Yan, et al., 1999).

19

γ-secretase

The γ-site on APP is cleaved by γ-secretase, a complex enzyme
made up of four components, presenilin (PS), nicastrin (NCT), aph-1, and
pen-2. After β–secretase cleavage, γ-secretase processing of APP
generates the Aβ peptide. PS is an aspartyl protease that can incorporate
one of two homologous catalytic subunits, PS1 (Cruts, et al., 1995) and
PS2 (J. Li, Ma, & Potter, 1995). They have eight transmembrane domains
(TMD), and the active site resides between the sixth and seventh TMD (X.
Li & Greenwald, 1998). It is here where the two ASP required of aspartyl
protease activity are located. Mutation analyses showed that replacing
the aspartate for alanine reduced production of Aβ (Wolfe, et al., 1999).
This relationship had remained elusive due to the intra-membranous
location of the γ-site. Further progress in the identification of other intramembranous cleavages provided support for this obscure proteolytic
activity termed regulated intra-membrane proteolysis (RIP) (Lee, et al.,
2002; Ni, Murphy, Golde, & Carpenter, 2001; Sakai, et al., 1996;
Schroeter, Kisslinger, & Kopan, 1998).
20

Aspartyl proteases contain the D(T/S)G(T/S) consensus sequence
in the active site. Interestingly, PSs have a GxGD (where x is any amino
acid) in place of the D(T/S)G(T/S) residues in the active site. The GxGD
motif is also conserved in other enzymes that perform RIP, like type-4
prepilin peptidases (Steiner, et al., 2000) and signal peptide peptidases
(discussed in (Weihofen & Martoglio, 2003)). It has therefore been
suggested that these proteins form a new family of aspartyl-proteases
whose specialized intra-membranous cleavage activity requires a
modified sequence from the consensus aspartyl peptidase site (Haass &
Steiner, 2002).

Linkage analyses identified over 100 mutations leading to some of
the most common and aggressively progressing FAD pathologies in the
PS genes. Mice with the PS2 gene knocked out (PS2-/-) show no
significant change in phenotype from wild-type controls, except for mild
pulmonary fibrosis and increased ease of hemorrhage over time
(Herreman, et al., 1999). APP processing is not affected in these mice,
leading to the assumption that: (1) PS2 may play a minor role regarding
APP cleavage and (2) AD mutations on PS2 are gain-of-function
mutations. In contrast, PS1-/- mice show severe developmental
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deficiencies reminiscent of the Notch1-/- phenotype (discussed later)
(Herreman,

et

al.,

1999),

suggesting

that

PS1

plays

a

more

physiologically relevant role (Herreman, et al., 1999).

As stated previously, PS is a component of the γ-secretase complex.
As such, and based on experiments in different in vivo and in vitro
models, it’s γ-site cleavage activity is dependent upon the other four
components (Francis, et al., 2002). NCT has been mostly characterized
under scrutiny of its role in γ-secretase activity, and it has been shown to
be indispensable for secretase function (Edbauer, Winkler, Haass, &
Steiner, 2002; Hu, Ye, & Fortini, 2002; Leem, et al., 2002). Knockdown
and knockout experiments targeting NCT preclude maturation of the γsecretase complex (Edbauer, et al., 2002) and reduce or abolish
enzymatic activity (Hu, et al., 2002). Furthermore, PS1-/- cells exhibit
reduced levels of mature NCT, suggesting that NCT maturation is
dependent on its interaction with PS1 (Edbauer, et al., 2002). Genetic
screens in C. elegans identified aph-1 (Goutte, Tsunozaki, Hale, & Priess,
2002) and pen-2 (Francis, et al., 2002) as critical elements for γsecretase function. Moreover, pen-2 was found to co-immunoprecipitate
with NCT implying that it formed the γ-secretase complex (Steiner, et al.,
2002).
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These two proteins were quickly recognized as having important
roles in Notch processing, another substrate of γ-secretase cleavage.
Reduction of γ-secretase activity by downregulation or elimination of any
component of the complex results in a phenotype similar to the Notch-/models (discussed in (Haass & Steiner, 2002)). As briefly mentioned
above, Notch signaling pathway plays a key role in development. The
study of the molecular mechanisms driving this pathway revealed the γsecretase-mediated cleavage, or S3, of Notch to release a Notch
intracellular domain (NICD). This newly formed peptide translocates into
the nucleus and functions as an activator of gene transcription. Likewise,
the γ-secretase cleavage of APP releases an APP intracellular domain
(AICD) that is thought to have transactivating properties like NICD. AICD
promoter elements have not been completely identified. Together, these
two mechanisms underscore the way by which γ-secretase targets type-1
membrane proteins and release an S3 transcription factor. Other recently
identified proteins that undergo γ-secretase proteolysis are the APP
homolog APLP1, Notch 2-4, ErbB-4, E-Cadherin, CD44, Nectin1α, and LRP
(Haass & Steiner, 2002). However, the exact downstream effects of these
cleavages have not been conclusively characterized.
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Tau

The other major pathological hallmark present in AD brains is the
presence of neurofibrillary tangles (NFT), made of paired-helical filaments
(PHF) or τ-tangles. These structures are intracellular deposits of a
filamentous protein whose basic subunit is a toxic, misfolded, and
hyperphosphorylated τ (Grundke-Iqbal, et al., 1986; Iqbal, et al., 1974;
Kosik, Joachim, & Selkoe, 1986). Normally, as a microtubule-associated
protein (MAP), τ promotes elongation and stabilization of microtubules.
The human brain is capable of making six splice variants of τ (Goedert,
Spillantini, Jakes, Rutherford, & Crowther, 1989), which are mainly
phosphorylated by several kinases like glycogen synthase kinase-3
(GSK3) (Ishiguro, et al., 1993). Conversely, several phosphatases have
also been detected as modifiers of τ. Together, these enzymes keep a
balance of active and inactive τ to stabilize polymerization of tubulin into
microtubules. Interestingly, two of these enzymes, protein phosphatases
PP-2A

and

PP-1,

are

reduced

in

AD

brains,

resulting

in

τ-

hyperphosphorylation (Gong, Grundke-Iqbal, & Iqbal, 1994; Gong, Singh,
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Grundke-Iqbal, & Iqbal, 1993). While τ phosphorylation permits
disassociation

for

microtubule

breakdown,

self-aggregation

and

deposition of τ is triggered by hyperphosphorylation. This pathogenic
hyperphospho-τ form is not only incapable of promoting the formation
and stabilization of microtubules, but it also sequesters normal τ as well
as other microtubule stabilizers such as MAP1 and MAP2 (Alonso,
Grundke-Iqbal, & Iqbal, 1996; Alonso, Zaidi, Grundke-Iqbal, & Iqbal,
1994).

The

end

result

is

inhibition

and

disruption

of

tubulin

polymerization (Alonso, et al., 1994).

Pathogenic τ is present in two cellular pools: PHF and cytosolic
hyperphosphorylated τ. While the former is inert and incapable of binding
tubulin (Iqbal, Zaidi, Bancher, & Grundke-Iqbal, 1994); the latter
comprises 40% of the pathogenic τ. The cytosolic portion is the most
pathogenic as it is free to inhibit microtubule formation and stabilization
by impairing microtubule-associated proteins 1 and 2, and endogenous,
non-pathogenic tau (Alonso, et al., 1996; Alonso, et al., 1994; B. Li,
Chohan, Grundke-Iqbal, & Iqbal, 2007). Although AD brains have the
same amount of non-pathogenic τ as those of non-diseased individuals,
toxic τ levels are increased four to eight-fold in AD brains compared to
those of non-AD individuals (Khatoon, Grundke-Iqbal, & Iqbal, 1992,
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1994).
Since amyloid deposition seems to precede formation of PHF (Gotz,
et al., 2001; J. Lewis, et al., 2001), τ has been thought to be a
downstream component of toxicity and thusly less effective as a
therapeutic target. However, other neurodegenerative diseases frontotemporal

dementia,

progressive

supranuclear

palsy,

corticobasal

degeneration, and Pick’s disease, are called tauopathies as they are also
characterized by having NFT. The identification of τ as a component in the
pathology of these diseases underscores the toxic impact of τ in AD
dementia. In fact, as opposed to amyloid plaques, the amount of tangles
correlates better with the clinical diagnosis and degree of dementia in AD
patients (Arriagada, Growdon, Hedley-Whyte, & Hyman, 1992); patients
burdened with Aβ-plaques without the tangle component lack signs of
dementia (Arriagada, et al., 1992; Dickson, et al., 1988; Katzman, et al.,
1988).
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Cholesterol and the Risk of Alzheimer’s Disease

Cholesterol is vital to life because it is an essential component of
cell membranes, it is the starting molecule from which steroid hormones
originate, and it produces the bile for absorption of other fatty acids
necessary for life. In cell membranes, cholesterol provides rigidity that
can be used for protein docking, formation of lipid rafts, and to become
part of vesicles that will either be fused or evacuated from the plasma
membrane. Cholesterol is constantly shed from the cell membrane and
actively replenished so that the net amount of cholesterol in a cell
membrane remains constant. To maintain this equilibrium, a constant
cholesterol supply needs to be maintained. To meet this requirement,
almost every tissue in the body is capable of making and/or internalizing
cholesterol.

Elucidation of the pathways for biosynthesis, degradation, and
cycling of cholesterol has revealed the function of proteins that are
directly or indirectly involved in regulating cholesterol. Therefore,
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identification of some of these proteins in the CNS has allowed swift
strides in understanding how cholesterol is regulated in the brain. Some
of these players are the cholesterol transporter, apoE, and its main
receptors: LDLR, LRP (LDLR-related protein), VLDLR (very LDLR), and
apoER2 (Pitas, Boyles, Lee, Hui, & Weisgraber, 1987). However, the
differences between both peripheral and central compartments relay
distinctions between these players. For instance, the main cholesterol
transporter in CNS is apoE, whereas in the periphery there are many
other apolipoproteins that play a significant role in cholesterol circulation
such as apoB and apoA. The brain makes its own apoE that is
independent from the plasmatic pool (Linton, et al., 1991); and it also
differs in structure (Pitas, Boyles, Lee, Foss, & Mahley, 1987).
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Cholesterol Metabolism in the Brain

There is no experimental evidence proving that peripheral
cholesterol crosses to the CNS. Several studies concluded that lipoprotein
cholesterol did not cross the CNS at any age or region of the CNS. In
effect, 125I-labeled-LDL injected intravenously was virtually undetectable
in CNS of adult mice, sheep, and rabbit, while the liver and adrenal gland
took up LDL from 100 to 1000 µl/h/g (Osono, Woollett, Herz, & Dietschy,
1995; Spady, Huettinger, Bilheimer, & Dietschy, 1987). The same
observation was found in sheep at both the fetal and suckling stages,
which coincide with a very high level of cholesterol accretion due to brain
growth and myelination (Turley, Burns, Rosenfeld, & Dietschy, 1996).
Similar results were found with

14

C-labeled cholesteryl esters in HDL,

providing evidence that CNS impermeability to lipoproteins is not unique
to LDL (reviewed in (Dietschy & Turley, 2004)). Other efforts to find
potential pathways of cholesterol transport from serum to the brain have
been disproven. For instance, there was no change in CNS cholesterol
content or synthesis when deleting brain lipoprotein transporters like
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LDLR (Dietschy, Kita, Suckling, Goldstein, & Brown, 1983; Osono, et al.,
1995), SR-BI, or ABCA1 (Quan, Xie, Dietschy, & Turley, 2003). Finally,
increasing serum cholesterol by dietary means did not change the
cholesterol content in the CNS (Quan, et al., 2003). Therefore,
cholesterol metabolism in the CNS seems to be independent from
peripheral input.

This conclusion can be explained in part by the presence of the
blood-brain barrier (BBB) a cell-layered structure of unique endothelial
cells that cover every capillary irrigating the CNS and selectively filters
substances for entry to the CNS. Moreover, podocytic processes on
astrocytes adjacent to the endothelial cells form tight junctions further
reducing fenestrae and minimizing capillary exchange (Rubin & Staddon,
1999). Unlike other body regions where molecules can diffuse
paracellularly, permeable substances to the BBB must face the
endothelial cells parallel to the capillary (Stewart & Hayakawa, 1987).
The result is an obstreperous, highly selectively permeable cellular
membrane that protects the CNS by regulating the amount and type of
molecules that can come in contact with neural tissue. Selective
permeability is facilitated via specific transport proteins (Rubin &
Staddon, 1999); furthermore, like most membranes in the body, the BBB
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is permeable to water, and therefore some hydroxylated substances are
also capable of diffusing through to the CNS.

Evaluation of cholesterol transport across the BBB performed during
development yielded similar conclusions. Experiments in developing and
adult rats, baboons, and humans show that labeled cholesterol
administered intravenously, intragastrically, or by ingestion in the diet
was detected in peripheral organs like liver and adrenal glands; however,
such exogenous cholesterol was not detected above background in the
brain (Chobanian & Hollander, 1962; Edmond, Korsak, Morrow, TorokBoth, & Catlin, 1991; Wilson, 1970; G. Xu, et al., 1998). Since its
cholesterol requirement is vast and serum cholesterol is unable to form a
part of the brain’s sterol pool, the CNS must produce its own cholesterol
supply (Dietschy & Turley, 2004). For example, cholesterol synthesis has
been measured to be high in oligodendrocytes at the time of intensive
myelin formation during development (Fu, et al., 1998; H. Jurevics,
Bouldin, Toews, & Morell, 1998; H. A. Jurevics & Morell, 1994). This
effect correlates with myelin formation in the periphery, where Schwann
cells synthesize the cholesterol used to form myelin in axonic and
dendritic prolongations. Moreover, the rate of synthesis decreases as the
organism reaches adulthood (H. Jurevics & Morell, 1995; Muse, Jurevics,
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Toews, Matsushima, & Morell, 2001; Quan, et al., 2003). Presumably,
this occurs as myelin formation has culminated (Dietschy & Turley,
2004). During this stage of life, cholesterol accretion is lower than that of
synthesis, indicating that the net movement of cholesterol is towards
excretion. However, it has also been suggested that the disparity
between synthesis and accretion is due to basal maintenance of glial and
neuronal membranes (Spady & Dietschy, 1983). The uniqueness of CNS
cholesterol synthesis is also seen in that there is no evidence that CNSsynthesized cholesterol is packaged in lipoproteins (Dietschy & Turley,
2004).

The net flow of cholesterol exits the CNS into plasma, but in order
to cross the BBB, sterols must be modified to become permeable. The
enzyme cholesterol 24-hydroxylase (CYP46A1) is capable of modifying
cholesterol

into

a

permeable

molecule,

24(S)-hydroxycholesterol

(Dietschy & Turley, 2004). Both the detection of mRNA for CYP46A1
almost exclusively in the CNS (Lund, et al., 2003; Lutjohann, et al.,
1996) as well as identification of 24(S)-hydroxycholesterol’s capacity of
exiting the BBB from the CNS (Lutjohann, et al., 1996) suggested a
method of sterol flow from CNS to plasma. Once in serum, 24(S)hydroxycholesterol enters the liver where its conversion to bile acids and
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subsequent excretion takes place (Bjorkhem, et al., 2001). Levels of
24(S)-hydroxycholesterol in the developing mouse correlate with the
initial decline in cholesterol synthesis in CNS (Lund, Guileyardo, &
Russell, 1999). Interestingly, mRNA for CYP46A1 was mostly found in
neurons located in areas where the highest levels of myelin formation
takes place, suggesting that it is this type of cell that regulates
cholesterol turnover at the end of brain development (Lund, et al., 1999).
This observation further supports the excretion pathway of cholesterol
and contributes to the model of net cholesterol flow from the CNS during
different ages in the mouse.
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Cholesterol and Disease

Cholesterol’s function as a delimiting component of plasma
membrane and thereby its role as a mediator in cell-to-cell or cell-tomilieu interactions, make it subject to a wide range of pathogenic insults.
Specifically, as a component of liquid-ordered, detergent-resistant
membrane rafts (lipid rafts), cholesterol docks proteins that can be
intrinsic to the membrane, doubly acylated, palmitoylated, or anchored
by glycophosphatidyl inositol (GPI). These proteins perform a vast
number of functions for cell survival, development, or homeostasis.
Alterations to cholesterol in these membranes undoubtedly cause insults
to the cellular balance and, in most extreme cases, cause disease. Some
examples of diseases resulting from alterations to cholesterol in rafts are
AD, Parkinson’s disease, Niemann-Pick disease, diabetes, neoplasia,
atherosclerosis, B and T-cell response, asthma, and prion diseases,
among many others (K. Simons & Ehehalt, 2002).

Genetic disorders inducing hypocholesterolemia further underscore
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the importance of cholesterol in brain development. Smith-Lemli-Optiz
syndrome is characterized by the inability of patients to procure
cholesterol. As a result, multisystemic alterations ensue, such as
pulmonary deficit due to the inability to produce lung surfactant. Also,
neurodevelopment is altered, and these patients are characterized by
mental retardation (Salen, et al., 1996). Less severe cases where
cholesterol fluctuations occur have been postulated as the root causes of
behavioral diseases. For instance, low serum cholesterol levels have been
related to suicidal, criminal, and aggressive behavior and has led to the
hypothesis that reduced serum cholesterol may in turn reduce serotonin,
a hormone involved in behavior (Engelberg, 1992). In effect, these
individuals have lower serum serotonin levels (Engelberg, 1992; Muldoon,
Manuck, & Matthews, 1990). Also, hyper and hypocholesterolemia are
associated with all-cause mortality. Too high or too low cholesterolemia is
directly proportional to non-violent mortality rates (Iribarren, Reed,
Chen, Yano, & Dwyer, 1995; Jacobs, 1993; Muldoon, et al., 1990;
Peterson, Trell, & Sternby, 1981). However, these latter hypotheses are
based on association and have not been molecularly linked.

AD and atherosclerosis are discussed below. Associations between
cholesterol and these two diseases are population based, and their links
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have been further studied using animal models.

Cholesterol and Atherosclerosis

Cholesterol’s reputation has been besmirched by its role in
cardiovascular disease. Excess cholesterol from the diet leads to
atherosclerosis, a condition where lipid deposits laminate and eventually
obstruct the lumen of blood vessels (Small & Shipley, 1974). The result is
reduction in blood supply to the region where arteries (at the capillary
portion) irrigate. Atherosclerosis is especially damaging when it occurs in
the coronary arteries that feed the heart since their occlusion mainly
results in myocardial infarction and, in severe cases, leads to death
(Keys, 1975).

The population consuming western diets, where total concentration
of cholesterol is 300-500 mg of cholesterol/day (Berenson, et al., 1992;
L. A. Lewis, et al., 1957) compared to <100 mg of cholesterol/day in
Amerindians, tribes in Papua New Guinea, and rural Chinese is at high
risk for the fatal consequences of coronary occlusion (Z. Chen, et al.,
1991; Connor, et al., 1978; Dietschy & Turley, 2004; McMurry,
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Cerqueira, Connor, & Connor, 1991; McMurry, Connor, Lin, Cerqueira, &
Connor, 1985; Mendez, Tejada, & Flores, 1962; Sinnett & Whyte, 1973;
Whyte & Yee, 1958). As a result, these factors have prompted extensive
investigation of peripheral cholesterol metabolism. However, though
common, atherosclerosis-induced cerebro-vascular accidents have been a
second plane of cholesterol research. Consequently, there is poor
understanding of cholesterol homeostasis in the CNS.

Hypercholesterolemia is not only found as a consequence of diet,
but also from genetic predisposition. The most commonly studied form of
hypercholesterolemia is the latter condition, where a series of mutations
that affect proteins involved in cholesterol metabolism were analyzed.
Familial hypercholesterolemia (FH), an autosomal dominantly inherited
disease, is caused by mutations in a gene encoding a particular protein
called the LDLR. This receptor has the highest binding affinity for
apolipoprotein E (apoE). FH mutations lead to a reduction or ablation of
LDLR function, resulting in hypercholesterolemia. Patients who are
homozygous for FH mutations have no functional LDLR; this severe form
of the disease leads to early mortality typically by way of acute
myocardial infarction.
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Cholesterol and Alzheimer’s Disease

Cholesterol has been portrayed as an important link to AD
pathogenesis because 1) apolipoprotein E4, a cholesterol transporter, is
the main molecular risk factor for both AD and atherosclerosis (Corder, et
al., 1993); 2) hypercholesterolemia is an independent risk factor, as
increased levels of LDL-cholesterol in mid-life correlate with higher risk
for AD (Notkola, et al., 1998); 3) cognitively intact individuals with signs
of heart disease show prevalent amyloid plaque load compared to agematched individuals without cardiovascular ailment (Sparks, et al.,
1990); 4) AD patients have higher LDL, which correlate with Aβ levels
(Kuo, et al., 1998); 5) protective proteins against cardiovascular disease,
like HDL and apoA1, are decreased in AD patients(Merched, Xia, Visvikis,
Serot, & Siest, 2000); 5) Aβ production can be manipulated by modifying
the pools of membrane cholesterol (Fassbender, et al., 2001; M. Simons,
et al., 1998); 6) brains of rabbits fed a high-cholesterol diet present Aβ
deposits (Sparks, et al., 1994); 7) atherogenic diets accelerate Aβ
deposition in AD transgenic mice (Levin-Allerhand, Lominska, & Smith,
38

2002; Refolo, et al., 2000; Shie, Jin, Cook, Leverenz, & LeBoeuf, 2002);
and 8) atherosclerotic lesions and cognitive decline correlate with Aβ load
in transgenic AD mice backcrossed to a strain that is susceptible to
formation of atheromas (L. Li, Cao, Garber, Kim, & Fukuchi, 2003). Other
preliminary observations include the finding that individuals treated with
cholesterol-lowering drugs are at lower risk of AD (Buxbaum, Cullen, &
Friedhoff, 2002; Sjogren, et al., 2003); however, these results are
contradicted and remain unconfirmed (Fassbender, et al., 2002; M.
Simons, et al., 2002).

Studies carried out in vitro conclude that

cholesterol plays a role in modulating Aβ generation. Treatment of HEK
293 cells stably expressing full-length APP with lovastatin reduces
intracellular cholesterol by 50% and virtually inhibits secretion of
amyloidogenic products from APP cleavage (Frears, Stephens, Walters,
Davies, & Austen, 1999). Meanwhile, treatment of the same cells with
exogenous cholesterol induces a 4-fold increase in total secreted
amyloidogenic products and decreased products of APP cleavage by αsecretase (Bodovitz & Klein, 1996; Frears, et al., 1999). Interestingly,
while 1.8-fold of the increased amyloidogenic species correspond to Aβ40,
Aβ42 levels are decreased (Frears, et al., 1999) in the media. Cholesterol
reduces glycosylation and consequently the cleavage of APP into nonpathogenic products (Galbete, et al., 2000). Cellular vesicle transport is
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reduced when exposed to pathogenic Aβ; this alteration is replicated by
treatment with low levels of extracellular cholesterol. Together, these
studies indicate that exogenous cholesterol provokes Aβ production and
reduces α-secretase cleavage products. However, the exact mechanisms
are unclear. These studies measure APP-products in the media, yet
intracellular Aβ42 is unaccounted upon cholesterol-induced production of
Aβ. It can be inferred that Aβ42 may cause intracellular toxicity leading to
cell death.

Overall,

the

elucidation

of

cholesterol’s

involvement

in

neurodegenerative diseases has been elusive and this is partly due to the
difficulty of accessing the CNS in vivo for analytical studies. Nevertheless,
several groups have evaluated 24(S)-hydroxycholesterol as a measure of
cholesterol efflux during disease (Bjorkhem & Meaney, 2004) and in the
case of AD, it was found that there is an initial increase in serum 24(S)hydroxycholesterol (Heverin, et al., 2004; Papassotiropoulos, et al.,
2002; Papassotiropoulos, et al., 2000; Schonknecht, et al., 2002). Other
studies revealed that CYP46A1 expression is shifted ectopically from
neurons to glia in AD patients, which should result in decreased 24(S)hydroxycholesterol (Bogdanovic, et al., 2001; J. Brown, 3rd, et al.,
2004). The conflict in these results can be settled by underscoring the
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timing between these measurements, as an initial peak of 24(S)hydroxycholesterol could be the result of demyelination, while the
reduction in CYP46A1 expression could be the result of neuronal loss, as
it is neurons that make this enzyme. Ultimately, AD patients have
increased serum levels of another oxysterol that can evacuate the CNS by
a CYP46A1-independent pathway. Conversion of cholesterol to 27hydroxycholesterol is presumed to be accountable for the major sterol
excretion from the CNS seen in AD. Unfortunately, there is a lack in
confirmatory reports or even studies deepening the understanding of
cholesterol flow during neurodegenerative diseases (Dietschy & Turley,
2004).
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Apolipoprotein E Isoforms and Disease

ApoE is a 34 kDa, 299-amino acid glycoprotein and is the chief
cholesterol transporter in the central nervous system (CNS). In the
periphery, apoE is a major component of VLDL. Aside from its
involvement in cholesterol transport, apoE also participates in peripheral
nerve recovery, pathogenic chaperoning of Aβ (T. Wisniewski &
Frangione, 1992), and signal transduction by way of the various
receptors it is able to bind (Strittmatter, 2001).

The APOE gene, located on chromosome 19q13, may code for any
homozygote or heterozygote combination of three isoforms—apoE2,
apoE3, and apoE4 (Havel & Kane, 1973; Zannis, Just, & Breslow, 1981).
Structure-function differences between the apoE isoforms increase the
risk for several diseases. The E4 isoform of apoE is the strongest
molecular risk factor for AD onset. It is estimated that 60% of LOAD
cases are attributable to the apoE4 isoform (Rubinsztein & Easton, 1999),
and about 60-80% of all AD patients have at least one copy of apoE4
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(Mahley, Weisgraber, & Huang, 2006; Saunders, et al., 1993;
Strittmatter, et al., 1993). Furthermore, the risk for AD is increased in an
allelic dose-dependent manner where two copies of apoE4 result in higher
risk than any other isoform combination (Corder, et al., 1993).

The isoforms differ in both the frequencies with which they are
found in the population as well as in the primary structure in amino acids
112 and 158: apoE2 (frequency of 2-5%) has a cysteine in each one of
these sites; apoE3 is the most common (65-70%) and has Cys-112 and
Arg-158; finally, apoE4 (15-20%) has two arginines at these sites (Rall,
Weisgraber, & Mahley, 1982; Weisgraber, Rall, & Mahley, 1981).
Structural differences affect the lipid content of the isoforms, where Arg112 on E4 makes it more favorable for carrying large, triglyceride-rich
VLDL particles, rather than smaller phospholipids on HDL. Furthermore,
the apoE4 substitutions elicit a stronger interaction between the Cterminal and N-terminal domains, rendering a more compact structure
than apoE3 (Mahley, 1988; Mahley & Rall, 2000; Weisgraber, 1994).

In the CNS, apoE-cholesterol is principally made in astrocytes and
exported to neurons (Boyles, Pitas, Wilson, Mahley, & Taylor, 1985;
Elshourbagy, Liao, Mahley, & Taylor, 1985); however, neurons can also
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produce apoE-cholesterol during stress (Q. Xu, et al., 2006). Despite
expressing several receptors that are capable of internalizing apoE, such
as low-density lipoprotein receptor (LDLR), LDLR-related protein (LRP),
apoER2, and VLDLR, neurons mainly import apoE via the LDLR
(Innerarity & Mahley, 1978; Innerarity, Pitas, & Mahley, 1979; Mahley,
1988; Mahley & Rall, 2000).
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Low-Density Lipoprotein Receptor (LDLR) and Disease

While investigating the causes of Familial Hypercholesterolemia,
Brown and Goldstein characterized the LDLR and elucidated the process
of receptor-mediated endocytosis (Goldstein & Brown, 1976). For this
work, they were awarded the Nobel Prize in 1985. They described the
LDLR as a membrane-spanning glycoprotein that plays a critical role in
removing LDL and VLDL from the blood (Sudhof, Goldstein, Brown, &
Russell, 1985). Under low intracellular sterol levels, LDLR gene
expression is primarily and directly activated by sterol response elementbinding proteins (SREBPs) (Smith, Osborne, Goldstein, & Brown, 1990)
and secondarily by thyroid hormone (Lopez, Abisambra Socarras, Bedi, &
Ness, 2007). Translation of the mRNA yields a 120 kDa protein that is
further post-translationally modified in the Golgi apparatus into a mature,
160 kDa protein (Tolleshaug, Goldstein, Schneider, & Brown, 1982;
Yamamoto, et al., 1984). It has been classified as having five regions: an
N-terminal ligand-binding domain (LBD) (Sudhof, Goldstein, et al., 1985;
Sudhof, Russell, et al., 1985), an epidermal growth factor precursor
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homology domain (Davis, Goldstein, et al., 1987; Sudhof, Russell, et al.,
1985), an O-linked polysaccharide domain (Davis, et al., 1986) where the
protein is post-translationally modified, a membrane-spanning domain
(Goldstein, Brown, Anderson, Russell, & Schneider, 1985; Lehrman,
Russell, Goldstein, & Brown, 1987; Lehrman, et al., 1985), and a Cterminal cytoplasmic domain (Goldstein, et al., 1985). Upon maturation,
the LDLR is transported to the cell membrane as a clathrin-coated pit
vesicle (Davis, van Driel, Russell, Brown, & Goldstein, 1987). On the
membrane, the LBD is exposed to bind and internalize LDL or VLDL,
mediated by apoB or apoE binding to LDLR, respectively. Once inside the
cell, the LDLR-ligand-containing vesicle undergoes acidification by proton
pumps (M. S. Brown & Goldstein, 1986), leading to uncoupling of the
receptor-ligand complex. At this point, the LDL or VLDL-cholesterol
undergoes further processing to be readily available for the cell’s
requirements. Meanwhile, the LDLR can be either recycled or degraded.
The latter case occurs in a poorly understood process that involves the
proprotein convertase subtilisin/kexin type 9 or neural apoptosisregulated converstase-1 (PCSK9/NARC1), the main regulator of LDLR
turnover (Maxwell & Breslow, 2004; Maxwell, Fisher, & Breslow, 2005;
Park, Moon, & Horton, 2004). This property was elucidated by
characterizing the physiological implications of mutations leading to gain
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(Abifadel, et al., 2003; Allard, et al., 2005; Cameron, et al., 2008; S. N.
Chen, et al., 2005; Leren, 2004; Miyake, et al., 2008; Scartezini, et al.,
2007; Sun, et al., 2005; Timms, et al., 2004) and loss of PCSK9 function
(Abboud, et al., 2007; Berge, Ose, & Leren, 2006; Cameron, et al., 2008;
Cohen, et al., 2005; Fasano, et al., 2007; Miyake, et al., 2008;
Scartezini, et al., 2007; Zhao, et al., 2006), which result in LDL-induced
hypercholesterolemia and hypocholesterolemia, respectively.

Linkage analyses were based on the fact that the LDLR gene locus
and a region associated with high frequency of AD risk share a common
location on chromosome 19 (Blacker, et al., 2003; Wijsman, et al.,
2004). Furthermore, this peak of risk for AD onset is independent of the
risk imparted by the apoE gene (Wijsman, et al., 2004). Consequent
attempts to characterize linkage of LDLR and AD onset yielded at least
ten, case-control association studies and one family-based study (Cheng,
et al., 2005; Corder, et al., 2006; Gopalraj, et al., 2005; Lamsa, et al.,
2008; Lendon, et al., 1997; H. Li, et al., 2008; Papassotiropoulos, et al.,
2005; Retz, et al., 2001; Rodriguez, et al., 2006; Scacchi, et al., 2001;
Zou, et al., 2008). Of particular interest were polymorphisms contained in
exons 8, 10, 13, and 15, as they had been proposed to have associations
with risk of AD onset (Cheng, et al., 2005; Gopalraj, et al., 2005; Retz, et
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al., 2001). The overall conclusion of these studies is not yet clear.

Other conflicting reports investigating LDLR’s participation in AD
have taken place at the biological level (Cao, Fukuchi, Wan, Kim, & Li,
2006; Fryer, et al., 2005; Thirumangalakudi, et al., 2008). The purpose
for these studies was to investigate whether elimination of LDLR
expression would affect the AD pathology in mouse models of the
disease. To this end, Fryer et. al. and Cao et. al. crossed the LDLR-/mouse with AD mouse models: the PDAPP and Tg2576, respectively. Both
groups agree that LDLR is the main regulator of apoE in CNS as they
observed a significant increase in apoE levels in the CNS of their
respective mice. However, Fryer et. al. did not see changes in the
Alzheimer’s pathology. On the contrary, Cao et. al. report a mild yet
significant increase in plaque deposition; furthermore, this study also
reported that the mice performed poorly on a battery of cognitive tests.

Dietary cholesterol modulates the rate at which APP is processed
into Aβ. Studies using animals fed high cholesterol diets revealed an
increase in amyloid plaque formation in rabbits and in transgenic mouse
models of AD (Howland, et al., 1998; Shie, et al., 2002; Sparks, et al.,
1994); moreover, in these mice, the high cholesterol diet also induced
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cognitive decline (Thirumangalakudi, et al., 2008). In vitro studies
demonstrated that APP processing is highly dependent upon the
availability of cellular cholesterol. Cholesterol-depleted rat hippocampal
primary neurons show reduced APP processing into Aβ (Fassbender, et
al., 2001; M. Simons, et al., 1998) yet favor the generation of nonamyloidogenic APP processing by α-secretase (Bodovitz & Klein, 1996;
Kojro, Gimpl, Lammich, Marz, & Fahrenholz, 2001).

These biochemical studies employed strategies and approaches that
attempted to elucidate the effects of LDLR on amyloid pathology in AD
mice. However, the question of whether LDLR is involved in AD
pathogenesis and/or progression remains unanswered. Consequently, our
approach was to determine the effects of amyloid pathology on LDLR
expression and localization. The results described in chapter 3 show that
overexpression of APP/Aβ increased LDLR expression and causes it to
accumulate in the trans-Golgi network (TGN) by affecting microtubule
organization. The implications are that LDLR function will be impaired. A
normal response of decreased levels of intracellular cholesterol is
transcriptional activation of the metabolic pathways leading to increased
cholesterol import and de novo biosynthesis. Consistent with these
results is the upregulation of LDLR mRNA as a sign of reduced
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intracellular cholesterol. These effects could result in dysregulated
cholesterol metabolism with increased membrane cholesterol, which in
turn favors Aβ production.

Another implication is that APP/Aβ-induced microtubule damage
would inherently affect protein trafficking, vesicle transport, and
cytoskeletal support provided by the microtubule network. Taken
together, these events may represent components of AD pathogenesis
and or progression, and thusly merit further study.
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Final Introductory Remarks

The work presented in the following chapters provides further
insight into the role of LDLR in AD pathogenesis and/or progression. The
current knowledge of the LDLR and AD relationship is controversial in that
both population studies and basic research approaches reach conflicting
results, which grant or remove participation of LDLR in the pathogenic
process of Alzheimer’s disease. At best, one may conclude that different
populations harbor specific polymorphisms in the LDLR gene that result in
changes in cholesterol homeostasis.

The common mouse model for the study of atherosclerosis is the
LDLR-/- mouse model of hypercholesterolemia (Cao, et al., 2006; Fryer,
et al., 2005; Thirumangalakudi, et al., 2008). In principle, this mouse
model is expected to be deprived of LDLR and should therefore facilitate
the evaluation of LDLR’s downstream effects. These effects were studied
with a focus on specific interactions with cholesterol levels in serum and
CNS, cholesterol homeostasis on a high-cholesterol diet, AD pathology,
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and cognition. The selection of cholesterol and apoE as targets for
evaluation is appropriate as they are independent risk factors of AD.
Likewise, the assessment of changes in AD pathogenesis or cognition was
performed using a mouse model consisting of a cross between the LDLR/- and other AD mouse models.

Our first objective was to study the LDLR-/- model to assess
whether it is a valid model for evaluating the effect of LDLR absence in
AD. We surmised that defects in the models could result in opposing
outcomes. In fact, Thirumangalakudi et. al. discuss this problem in their
report by delineating differences in AD model backgrounds and ages at
which the mice were evaluated in the studies by Fryer, et. al. and Cao,
et. al. Nonetheless, they used the LDLR-/- model as a validated
transgenic vehicle with precluded LDLR production.

Our second objective was focused on characterizing possible
alterations to the expression and localization of LDLR in AD. Specifically,
we investigated the effects of overexpressing APP/Aβ in in vivo and in
vitro models on LDLR expression and localization. While previous studies
by others evaluated the absence of LDLR in AD models, we sought to
determine how APP overexpression altered the expression or location of
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LDLR.
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UPREGULATION OF A FUNCTIONAL, STRUCTURALLY HOMOLOGOUS
SPLICE VARIANT OF LOW0DENSITY LIPOPROTEIN RECEPTOR IN
LDLR-/- AND ALZHEIMER’S DISEASE MICE

Abstract

Alzheimer’s disease (AD) is the most prevalent form of age-associated
dementia. Besides age, the most important risk factor associated with AD
onset is the inheritance of the ε-4 allele of apolipoprotein E. ApoE is a
cholesterol carrier that is internalized by neurons primarily via the lowdensity

lipoprotein

receptor

(LDLR).

We

sought

to

compare

apoE/cholesterol uptake by LDLR in the brains and livers of nontransgenic (NTG) and LDLR-/- mice. RT-PCR experiments revealed the
presence of a LDLR mRNA that lacks exon 4 (LDLRΔ4) in NTG mice and
that is upregulated LDLR-/- mice. Because LDLR transcription in LDLR-/mice is interrupted by insertion of a neo cassette with an RNA
cleavage/polyA addition site in this exon, the Δ4 alternative splicing event
91

evidently bypasses the knock-out scheme. Indeed, immunofluorescence
and immunoblot assays detected a LDLR-like protein in LDLR-/- brain
whose distribution in the brains of LDLR-/- mice coincides with that of
LDLR expression in NTG mice. To determine LDLRΔ4 function,
immunohistochemistry and functional assays were used to show that this
LDLR-like variant binds and internalizes apoE. Finally, RT-PCR showed
that the AD, double-transgenic mouse model, PS+/-APP+/-, expresses
higher levels of LDLRΔ4 in brain than the NTG control. Our findings
indicate that an assessment of association between LDLR and AD will
require a new knock-down model that totally eliminates LDLR in brain.
Similar alternative splicing may interfere with other knock-out mice.
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Introduction

Apolipoprotein E (apoE) is pivotal for CNS cholesterol distribution
(Boyles, et al., 1985; Elshourbagy, et al., 1985) and is the main protein
component of the very low-density lipoprotein (VLDL) particle in the
blood (Blum, Aron, & Sciacca, 1980; Mackie, Caslake, Packard, &
Shepherd, 1981). Consequently, alterations in apoE metabolism result in
a series of lipid-related disorders. The apoE4 isoform, in particular, is
linked to an increased risk for cardiovascular ailments (Mahley & Huang,
1999) and neurodegenerative diseases (Arnold, et al., 1997; Corder, et
al., 1993; Deane, et al., 2008; Hata, Kunugi, Nanko, Fukuda, &
Kaminaga, 2002; Ma, Yee, Brewer, Das, & Potter, 1994; Pickar, Malhotra,
Rooney, Breier, & Goldman, 1997; Potter, Wefes, & Nilsson, 2001;
Saunders, et al., 1993; T. Wisniewski, Castano, Golabek, Vogel, &
Frangione, 1994).

The main cellular receptor for lipidated apoE is the low-density
lipoprotein receptor (LDLR) (Fryer, et al., 2005). In contrast to our
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extensive knowledge of LDLR function and dysfunction in the periphery,
the role of LDLR in pathogenic pathways pertaining to the CNS is still not
fully understood (M. S. Brown & Goldstein, 1986). For example, because
both abnormal cholesterol metabolism and the presence of the apoE4
isoform of apoE are risk factors for sporadic, late-onset AD, the LDLR
may play a role as a potential mediator of AD pathology via its interaction
with apoE (5-13). Recent studies that investigated this relationship based
on LDLR-/- mice that had been crossed with AD mouse models, reported
conflicting conclusions (Cao, et al., 2006; Fryer, et al., 2005).

The mouse LDLR gene is composed of 18 exons that code for a 95
kDa protein (Goldstein, et al., 1985; Yamamoto, et al., 1984). Some of
these exons undergo alternative splicing, but potential alternative
functions of the resulting LDLR splice forms are unknown (Tveten,
Ranheim, Berge, Leren, & Kulseth, 2006; Zou, et al., 2008). The first five
LDLR exons encode the ligand-binding domain (LBD), which is composed
of seven, 40-amino acid repeats (R1-R7) (Goldstein, et al., 1985). Each
repeat is interspersed with six evolutionarily conserved cysteine residues
(Goldstein, et al., 1985). Site-directed mutagenesis studies showed a
marked decrease in LDLR binding to apoB by deletion of any repeat
between R2 and R7 (Esser, Limbird, Brown, Goldstein, & Russell, 1988;
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Russell, Brown, & Goldstein, 1989). In turn, deletion of R5, which is
encoded by exon 4, yielded maximal reduction of apoE binding (Russell,
et al., 1989). These data suggest that the apoE-binding region surrounds
R5 of the LDLR ligand-binding domain.

To further investigate the role of LDLR as a potential mediator of AD
pathology, we analyzed the LDLR expression profile in liver and brain of
NTG and LDLR-/- mice. Because of the likely importance of the apoE
binding site in LDLR for the receptor’s involvement in AD, we focused our
analysis on exon 4. Specifically, we evaluated the ability of LDLR-/- mice
to express a LDLR splice variant that lacks exon 4, because a LDLRΔ4
was recently described in humans (Neff, et al., 2003; Tveten, et al.,
2006). Not only would such a splicing event in mice affect LDLR binding
to apoE, but it would also bypass the knock-out scheme in the LDLR-/mouse, which is based on the interruption of translation by the insertion
of a neo cassette in exon 4 (Ishibashi, et al., 1993).

We report that LDLRΔ4 is expressed in both brain and liver in NTG
mice and is upregulated in LDLR-/- mice. Furthermore, the ability of
LDLRΔ4 to bind apoE is not impaired. Finally, our finding that LDLRΔ4 is
even more upregulated in a mouse model of AD and can bind and
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internalize apoE, suggests that LDLR may play an important role in the
apoE-related aspects of Alzheimer's pathology. These results also indicate
that

while

the

LDLR-/-

mouse

is

a

valuable

model

for

hypercholesterolemia studies in the periphery, the presence of an apoEbinding LDLRΔ4 splice-variant restricts its use for cholesterol research in
the CNS.
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Results

LDLRΔ4-variant mRNA is expressed in mouse liver and brain, and is
upregulated in both organs in LDLR-/- mice. In order to develop an
animal model for human hypercholesterolemia in which the potential for
LDLR gene therapy could be studied, Ishibashi et al. designed a LDLR-/mouse by interrupting exon 4 of the LDLR gene with a neo-encoding
cassette (Ishibashi, et al., 1993). The recombinant LDLR transcript should
generate a short mRNA that ends in exon 4 because cleavage and
polyadenylation is under direction of the neo cassette. Consequently, the
mice expressing this short mRNA fail to express full-length LDLR protein
in the liver. Physiologically, this LDLR-/- mouse is characterized by a 7.49-fold increase in serum LDL/IDL and a modest increase in VLDL and
HDL. This hypercholesterolemic phenotype is routinely enhanced by a
lipid-rich diet.

We sought to determine the relative amount of LDLR and its splice
variant, LDLRΔ4, in liver and brain of non-transgenic and LDLR-/- mice.
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Initially, we used an end-point PCR to identify the splice variant in brain
and liver of the LDLR-/- mice (Fig. 1). Primer A annealed to a sequence in
exon 3 (70 bp upstream of the 5’ end of exon 4), whereas primer B
bound to a sequence in exon 5 (35 bp downstream of the 3’ end of exon
4) (Fig. 1A). The presence or absence of exon 4 (comprising 384nucleotides) should change the size of the PCR product from 489 to 105
bp, respectively. Our data show that in NTG mice, full-length LDLR is
expressed in hippocampus, cortex, and liver (Fig. 1B). As expected, in
LDLR-/- mice, we did not detect full-length LDLR with this PCR strategy.
However, we did amplify a 105 bp product from LDLR-/- hippocampus,
cortex, and liver. DNA sequencing of the PCR products confirmed that the
amplified fragments correspond to exon 4-containing and exon 4-lacking
LDLR mRNAs.

To further confirm and quantitate LDLRΔ4 mRNA expression in NTG
and LDLR-/- tissues, we utilized quantitative RT-PCR. We designed two
sets of primer pairs and TaqMan probes that amplify either the exon 4-5
boundary that is unique to the full-length LDLR or the exon 3-5 junction
that is exclusive of the LDLRΔ4. Consistent with the end-point PCR
results, primer pairs that only recognize the exon 4-5 boundary did not
detect full-length LDLR mRNA in LDLR-/- mice (Fig. 2A). However, this
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approach detected trace amounts of LDLRΔ4 in NTG tissues (Fig 2B-D,
and Table 1). Furthermore in LDLR-/- mice, the LDLRΔ4 variant’s mRNA
was present and significantly upregulated in both brain and liver (Fig.
2D). In brains of LDLR-/- mice, the upregulated LDLRΔ4 transcript
amounts to 50% of the hepatic LDLRΔ4 mRNA (Table 1); this is far more
than the 1:20- brain/liver ratio of full-length LDLR in NTG mice. Keeping
in mind that in NTG mice the ratio of LDLRΔ4 to LDLR mRNA levels is
higher in brain (1:20) than in liver (1:221), our results suggest that
LDLRΔ4 may play a significant role in brain physiology.

Anti-LDLR antibody detects protein in LDLR-/- mouse brain. We used
a polyclonal antibody raised against the amino-terminus of the LDLR
(Ishibashi, et al., 1993) to assess the expression of LDLR in brain and
liver of LDLR-/- mice. As previously reported (Ishibashi, et al., 1993), we
did not detect LDLR bands in the livers of LDLR-/- mice (Fig. 3A).
However, we observed a band corresponding to a smaller LDLR in the
brains of NTG and LDLR-/- mice (Fig. 3B). The intensity of this band is
not significantly different between the two genotypes (Fig. 3C). In
addition, only in NTG brain we observed a smear above the LDLR
immuno-reactive band, which corresponds in size and heterogeneity to
glycosylated LDLR from the liver.
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In order to compare the cellular location and tissue distribution of
the LDLR-positive signal in LDLR-/- mice and NTG controls, we immunostained brain and liver sections from these mice. As expected, we
observed a large decrease in the LDLR signal in livers from LDLR-/- mice
compared to the NTG controls (Fig. 4B & H). In contrast, in the brains of
NTG and LDLR-/- mice the LDLR immuno-reactivity was equally strong
(Fig. 4A). This result was similar to the immunoblot results, which
showed equal signal intensity in the brains of both mice (Fig. 3B). To
confirm its specificity, the antibody was pre-incubated with a recombinant
LDLR protein prior to application to the tissue sections. The LDLR-reactive
signal was proportionally decreased in the brain sections that had been
incubated with the pre-adsorbed antibody (Fig. 4C). The signal
distribution across different brain regions was also conserved between
the LDLR-/- and NTG mice as determined by immuno-staining (Fig. 4DG). We further investigated the location of LDLR signal in primary
neurons from LDLR-/- and NTG mice. In both genotypes, immunostaining analysis revealed LDLR signal in vesicle-like structures
surrounding the soma and in the dendritic and axonal prolongations of
primary neurons (Fig. 4I).
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Primary and tertiary structure analysis show similarities between
LDLR and LDLR∆4. If the LDLRΔ4 expression in brain is to have
physiological significance, the LDLRΔ4 protein must either retain the
function of LDLR or acquire a novel function due to the excision of exon
4. We examined LDLRΔ4’s activity by first comparing its protein structure
to the structure of the full-length protein and then testing its apoEbinding capacity. Each of the seven repeats of the LDLR ligand-binding
domain (LBD) (R1-R7) has six conserved cysteines (Esser, et al., 1988)
(Fig 5A). Negatively charged residues are located in the carboxy-terminus
of each repeat, where they participate in ligand binding. ApoE binding
occurs in the area surrounding R5 (Esser, et al., 1988; Russell, et al.,
1989). Therefore, if LDLRΔ4 is to bind apoE in a similar manner to the
full-length LDLR, the protein must include features that are similar to the
region encompassing R5 in the full-length protein. Exon 4 codes for the
protein sequence of R3-R5 (highlighted in red in fig. 5A). The resulting
LBD of LDLRΔ4 is thus composed of R1, R2, R6, and R7 (Fig. 5B).
Consequently, in LDLRΔ4, R2 substitutes for R5 adjacent to R6.
Interestingly, an amino-acid sequence alignment of R5 with R2 shows
conservation of negatively charged residues and those that participate in
calcium coordination (Fig.5C). Both of these features are required for
ligand binding (Goldstein, et al., 1985; Yamamoto, et al., 1984).
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The sequence similarities between R2 and R5 together with R2's
position in the protein structure, suggested to us that R2 might have the
capacity to functionally replace R5 in the shortened LDLRΔ4 protein and
prompted a search for potential common tertiary structures of the apoEbinding regions of the LDLR and its LDLRΔ4 variant. Since R2/R6 in
LDLRΔ4 substitutes for R5/R6 in LDLR, we selected combinations of
double-repeat sequences of the LDLR ligand binding domain that
correspond to the region encoded by exon 4 (R2/R3, R3/R4, R4/R5,
R5/R6), and compared their predicted tertiary structures to that of the
fused double-repeat R2/R6 of LDLRΔ4 using the SWISS-PROT Repository
(ExPASy). The comparison showed that the double-repeat structure of
the apoE-binding region of LDLR (R5/R6) and LDLRΔ4 (R2/R6) are very
similar and completely different from the structures of all other LDLR
repeat pairs (Fig. 5D).

LDLR-positive signal in LDLR-/- primary neurons binds and
internalizes glia-derived apoE. Because the double repeat equivalents of
the LBDs from LDLR (R5/R6) and LDLR∆4 (R2/R6) predicted similar
structures (Fig. 5C and D), we hypothesized that they may have similar
functions as well. To investigate if the protein identified in LDLR-/- mice
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can function like LDLR, we tested its ability to bind glial-derived apoE.
ApoE was extracted from primary glial cultures and incubated with
primary neurons from NTG and LDLR-/- mice. Immunohistochemical
analysis showed that LDLR-/- primary neurons display similar LDLR
staining as NTG primary neurons (Fig. 6). In addition, apoE binding was
found to co-localize with the LDLR signal in both types of cells. As a
negative control, we incubated primary neurons without primary
antibodies and found no positive staining for either apoE or LDLR/LDLRΔ4
(data not shown). Furthermore, addition of 1 µM RAP blocked apoE
binding to NTG and LDLR-/- neurons (Fig. 6). These results indicate that
the LDLR-immuno-positive protein in LDLR-/- neurons is capable of
binding and internalizing apoE.

LDLRΔ4 is upregulated in PSAPP mice brains. Because the presence
of the apoE4 isoform of apoE is a risk factor for sporadic, late-onset AD
(Corder, et al., 1993; Saunders, et al., 1993), and because LDLR is the
main apoE receptor in the brain, it is important to investigate the role of
LDLR and LDLRΔ4 as potential mediators of AD pathology. To this end,
we quantified hippocampal and cortical mRNA from 11-12 month-old
PSAPP and NTG control mice. At this age, PSAPP mice are commonly
cognitively impaired, and amyloid plaques are prevalent in the
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hippocampus and cortex (Games, et al., 1995). Using RT-PCR we
detected equal expression of LDLR mRNA in the PSAPP model of AD and
age-matched NTG control mice (Fig. 7). However, the LDLRΔ4 variant
mRNA was found to be two-fold overexpressed in the brains of PSAPP
mice in comparison to the wild type mice (Table 2). Since both LDLR and
LDLR∆4 can bind and internalize apoE (Fig. 6), the upregulation of the
LDLR∆4 variant in mouse models of AD suggests that this splice variant
may play a role in the apoE-related mechanism of Alzheimer's pathology.
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Discussion

NTG mice express two types of LDLR mRNA: a full-length form and
a splice variant that is shortened by 384 nucleotides. Both forms are
expressed in brain and liver and the full-length form is more strongly
expressed in liver than in brain. In the brains of wild-type mice, the
LDLRΔ4 variant amounts to about 5% of the total LDLR. In the brains of
LDLR-/- mice, LDLRΔ4 mRNA is 653-fold upregulated in comparison to
wild-type animals. We also found that primary neurons of these LDLR-/mice are capable of binding and internalizing apoE. Based on the
upregulation of LDLRΔ4 mRNA, it is likely that the protein identified in
LDLR-/- mice is LDLRΔ4. The LDLR antibody we utilized for LDLR
detection recognizes an epitope upstream of the exon 4-encoded
fragment and thus should recognize both LDLR and LDLRΔ4. Western blot
analysis for LDLR in mice reveals a range of bands between 95 and 130
kDa, which represent different states of post-translational modification.
The LDLR-like protein detected in LDLR-/- brain showed a molecular
weight of 95 kDa, which corresponds to the lower end of the range of
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full-length LDLR signal that was identified in NTG brain (Fig 4B). In
addition, immunohistochemical assays revealed that the LDLR signal in
LDLR-/- and NTG tissues resembled the intensity observed in western
blots, and it was similarly distributed across different brain regions.

LDLR is the primary receptor for lipidated-apoE, which in turn is the
primary lipid carrier in brain. Disruption of the LBD at the apoE-binding
juncture precludes apoB binding (Esser, et al., 1988; Russell, et al.,
1989) and is expected to reduce apoE’s linkage to the receptor. However,
apoE-binding properties and structure are conserved between the fulllength LDLR in LDLRΔ4. Furthermore, we found LDLR and lipidated-apoE
co-localization in primary neurons of NTG and LDLR-/- mice. These data
suggest that LDLR-/- mice are able to internalize apoE via a LDLR-like
protein.

In 2005, Fryer et al. and Cao et al. crossed the LDLR-/- mouse with
different mouse models of Alzheimer’s disease (PDAPP and Tg2576) (Cao,
et al., 2006; Fryer, et al., 2005). Although the conclusions of the reports
contradict each other, resulting in an unclear understanding of LDLR’s
role in AD, they shed light on the characteristics of the LDLR-/- mouse
regarding LDLRΔ4. For instance, they show that apoE is increased by
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60% in LDLR-/- cortex and CSF. This result was corroborated by Elder et
al. (Elder, et al., 2007), who additionally found a decrease in apoE mRNA.
While this observation may seem paradoxical, it could suggest that total
apoE-binding is knocked down in LDLR-/- cortex and apoE translation is
upregulated as a compensatory response. Alternatively, the observation
may indicate that a higher amount of apoE has been internalized by
LDLR-/- mouse cells leading to a reduced transcription of the apoE gene.

We found that LDLRΔ4 mRNA is upregulated two-fold in the brains
of PSAPP mice. Because LDLRΔ4 internalizes apoE, its overexpression
should lead to increased intra-neuronal apoE. Another way to increase
apoE is by feeding high-cholesterol diets. Such food induces cognitive
deficits in NTG mice and promotes amyloid plaque formation in rabbits
(Sparks, et al., 1994) and APP transgenic mice (Blacker, et al., 2003;
Refolo, et al., 2000; Shie, et al., 2002). ApoE has previously been shown
to be a necessary chaperone for the promotion of amyloid plaque
deposition in AD mice (Ma, et al., 1994; Potter, et al., 2001; T.
Wisniewski, et al., 1994). As APP processing is proposed to take place
inside the cell, the intracellular increase in apoE, endogenous or
imported, will promote oligomerization of Aβ into fibrils, which will then
be secreted into the extracellular space. Therefore, it seems likely that
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the augmented amyloid plaque deposition in LDLR-/- mice found by Cao
et al. (Cao, et al., 2006) is apoE-related, rather than being a mere
consequence of diminished LDLR. The combination of increased Aβ and
apoE in the LDLR-/-xTg2576 mice should thus be sufficient to trigger and
promote increased amyloid plaque deposits and induce cognitive deficits
by increasing the relative intracellular concentration of these two
essential amyloid components.

In sum, our results describe an alternative-splicing phenomenon
that bypasses the knock-out strategy in the LDLR-/- mouse. Despite
effective use of this model to study the implications of systemic, apoBinduced hypercholesterolemia, interpretation of apoE-related changes in
cholesterol metabolism in the CNS is problematic. As a result, we propose
that a re-interpretation of previous data acquired by the utilization of the
LDLR-/- mouse for LDLR-mediated apoE metabolism in the brain is
appropriate.

To our knowledge, the only other example of a related knockout
escape by alternative splicing was described for the sorLA/R11 knock-out
mouse during the preparation of this manuscript. The sorLA/LR11 knockout mouse also undergoes an identical splice-mediated elusion of the
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knock-out scheme as we preliminarily reported in the LDLR-/- mice
(Abisambra, Padmanabhan, Wefes, Neame, & Potter, 2007; Dodson, et
al., 2008). The results also implicate deletion of exon 4, the site where
the new RNA cleavage and poly-adenylation site was introduced in the
sorLA/LR11-/- mouse. At the mRNA and protein level, the authors found
similar results to ours, implying that this alternative splicing activity may
be common in the LDLR family of proteins. Together, these results
support the conclusion that exon skipping must be considered while
targeting an exon for knock-out mouse generation. More research to
determine the normal function of splice variants of LDLR and SorLA/LR11
should prove valuable in determining if these shortened proteins work
independently or in concert with the cholesterol and apoE metabolism.
Furthermore, search for other splicing motifs within gene families may
shed light on unprecedented regulation of the functions of the products of
such gene families. In the case of LDLR, the exon 4 splice variant may be
expressed to eliminate ligand competition between apoB and apoE. If so,
this phenomenon might be a more efficient pathway for apoE
metabolism. Participation of other LDLR-family members and their splice
variants in cholesterol regulation remains to be determined.
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Materials and Methods

Materials: Quantitative-PCR experiments were performed using products
from Applied Biosystems, which include PCR master mixes, mouse
GAPDH endogenous control assays, gene expression assays for LDLR
exon 4-5 boundary (assay ID Mm01151338_m1), and a custom gene
expression assay for LDLRΔ4 detection. Tissue culture reagents and
electrophoresis

supplies

were

purchased

from

Gibco/Invitrogen.

Recombinant mouse LDLR was purchased from R&D Systems. Protein
concentrations were determined with BCATM (Pierce) colorimetric assays.
Antibodies: Rabbit anti-LDLR antiserum was used as primary antibody for
immunoblots (1:1000) and immunohistochemistry assays (1:100)
(Ishibashi, et al., 1993; Russell, et al., 1984). Monoclonal mouse antiactin (Sigma-Aldrich) and AlexaFluor 488 and 594 (Invitrogen/Molecular
Probes) antibodies were diluted according to the manufacturer for
western blot (WB) and immunohistochemistry (IHC) assays, respectively.
Goat anti-mouse IRDye®800CW and goat anti-rabbit IRDye®680 were
purchased from LI-COR Biosciences (WB: 1:15,000; IHC: 1:1500). Mouse
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anti-apoE monoclonal antibody (BD Biosciences LaboratoriesTM) was used
for WB, IHC, and immuno-purification of lipidated-apoE. This last
procedure was done with tosyl-activated, magnetic beads (Dynal Biotech)
according to manufacturer’s specifications and is described below.

Animals: All procedures involving experimentation on animal subjects
were done in accord with the guidelines set forth by the University of
South Florida’s Institutional Animal Care and Use Committee (IACUC).
The LDLR-/- mouse (B6.129S7-Ldlrtm1Her/J) was obtained from The
Jackson Laboratory (Ishibashi, et al., 1993). Mice with the genotype
APP+/-, PS1+/- were generated by crossing heterozygous PDGFhAPP(V717F) mice [Swiss-Webster X C57BL/6] with PDGF-hPS1(M146L)
heterozygotes [Swiss-Webster X C57BL/6] as described (Costa, et al.,
2007). Non-transgenic (NTG) control mice for LDLR-/- mice were
C57BL/6J expressing endogenous LDLR (The Jackson Laboratory). NTG
control mice for APP+/-, PS1+/- were littermates that lacked both
transgenes. All mice were genotyped by PCR to confirm the presence or
absence of LDLR (Ishibashi, et al., 1993; Soriano, Montgomery, Geske, &
Bradley, 1991), PDGF-hAPP

(Games, et al., 1995), and PDGF-hPS1

(Duff, et al., 1996).
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Tissue preparation: Brains and livers were acquired by anesthetizing mice
with 0.1 mg/g Nembutal followed by transcardial perfusion with 0.9%
saline solution for 8-12 min at 120 mmHg. Portions of the left, right, and
median lobe of the mice livers, as well as whole brains were immediately
removed for processing. Messenger RNA was extracted by homogenizing
tissues in TRI reagent (Sigma-Aldrich). Only cortices and hippocampi
were processed for brain mRNA isolation; All liver extracts consisted of
the same liver portions for each mouse. Microsome protein extracts were
obtained as previously described (Ness, Sample, Smith, Pendleton, &
Eichler, 1986), with minor modifications: 0.25M sucrose was prepared
with protease inhibitors (1 tablet mini-Complete/ 10 ml sucrose, Roche
Applied Science). Samples were spun once at 30,000 x g for 90 min in a
fixed-angle rotor. Microsome pellets were resuspended in PBS with 10%
glycerol

and

protease

inhibitor

cocktail

(Roche).

Brains

for

immunohistochemistry assays were fixed for 24 hrs in 4% paraformaldehyde. The fixed tissues were cryo-protected in successive
sucrose gradients as previously described (Nilsson, et al., 2001). Brains
were frozen on a temperature-controlled freezing stage, coronally
sectioned (25 µm) on a sliding microtome, and stored in a solution of PBS
containing 0.02% NaN3 at 4oC.
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End point RT-PCR and quantitative RT-PCR: Five micrograms of DNasetreated mRNA were reverse-transcribed with SuperScript® VILOTM cDNA
Synthesis Kit (Invitrogen) using random hexamers according to the
manufacturer’s instructions. Endpoint PCR was conducted using primer A
(sense): 5’– TGCATTCCTGACTCCTGGAGATGT -3’ and Primer B (antisense): 5’ –ACACTGGAATTCATCAGGTCGGCA -3’ (IDT). Thermal cycling
conditions were 95°C for 5 min, 35 cycles of 95°C for 30 seconds, 56°C
for 60 seconds, and 72°C for 60 seconds. PCR products were analyzed in
1.5% TAE-agarose gels stained with ethidium bromide. Gels were
scanned with the Alpha Imager (Alpha Innotech). Copy-DNA was
recovered from the bands and sequenced at H. Lee Moffitt Cancer Center
& Research Institute DNA Sequencing Core. Quantitative RT-PCR was
performed according to manufacturer. Custom gene-expression assay for
LDLRΔ4

detection

contained

a

sense

primer

(5’

–

TGGACAGGTAGACTGTGAAAATGAC -3’), an anti-sense primer (5’ –
CATCTGCACACTGGAATTCATCA- 3’), and a FAM-conjugated, MGBTM probe
(5’ –AACAAGGCTGTCCGGTGG -3’); the resulting PCR product spans the
exon 3-5 boundary. Quantitative-PCR reactions were processed in the
7500 FAST System with its Sequence Detection Software (SDS) from
Applied Biosystems.
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Western blots: Unless otherwise indicated, 15 µg and 50 µg (protein) of
liver and brain microsomes, respectively, were denatured with LDS
sample buffer according to the Invitrogen protocol. Samples were loaded
onto 3-8%, 1.0 or 1.5mm Tris-Acetate gels, and run at 80V for 180 min.
Gels were dry-transferred onto PVDF membranes for 9 min (iBlot,
Invitrogen). Non-specific protein binding to the membrane was blocked
by incubating with 5% BSA for 90 min at room temperature. Primary
antibodies for actin and LDLR were diluted 1:10000, and 1:1000

in

blocking buffer and incubated overnight at 4°C. Monoclonal mouse antiactin antibody and secondary antibody incubations with IR-dyes
(1:15000) were performed sequentially for 60 min at room temperature.
Membranes were washed three times for 10 min with PBS and 0.1%
Tween-20 after incubation with each antibody. Membranes were scanned
and analyzed with the LI-COR Odyssey and accompanying software.

Immunohistochemistry:

Brain

sections

were

mounted

onto

Colorfrost®/Plus slides (Fisher Scientific). Non-specific binding was
blocked in NGS (10% normal goat serum, 0.2% Triton X-100, and 0.02%
NaN3 in Tris-buffered saline (TBS)) for 120 min at room temperature.
Primary antibodies were incubated overnight at 4°C in 10% NGS. After
four 5 min washes in TBS, slides were incubated with secondary
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antibodies (IR-dyes or AlexaFluor) in 10% NGS for 60 min at room
temperature and washed in TBS. Slides were stained with Hoechst
(1µg/ml in PBS) for 2 minutes to reveal cellular nuclei and mounted using
GelMount (Fisher Scientific). Staining was analyzed with the Zeiss
AxioImager.Z1 and AxioVision software.

ApoE binding studies: Primary glial cells were isolated from E18 fetuses of
NTG mice (Padmanabhan, Levy, Dickson, & Potter, 2006) and cultured in
75 cm2 flasks coated with poly-lysine D (50 µg/ml). The tissue culture
supernatant from these cells was used for purification of lipidated-apoE.
The ApoE purification protocol (Fagan, et al., 1999) was modified by
immuno-purifying lipidated apoE with an anti-apoE antibody conjugated
to magnetic beads. Conjugation, purification, and elution were done
according to manufacturer’s specifications (company). Cortical and
hippocampal neurons were isolated from E18 fetuses of LDLR-/- and NTG
controls as described (Padmanabhan, et al., 2006). Primary neurons were
grown for one week on poly-L-lysine-coated 8-chamber slides in
neurobasal media with B27 supplement and then treated with 0.5 µM
lipidated apoE for 60 min at 37°C. Control cells were treated with 0.5 µM
lipidated apoE that had been pre-incubated overnight at 37°C with 1 µM
receptor-associated protein (RAP), a dose that effectively blocks ligand
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binding to LDLR family members (Fryer, et al., 2005; Medh, et al., 1995).
Cells were washed in PBS and then fixed in 4% para-formaldehyde for 10
min. Slides were immuno-stained for LDLR and apoE as described above.

Protein modeling: Three-dimensional images were created in the
alignment mode functionality of the SWISS-MODEL Repository from
ExPASy. Sequences spanning different two-repeat combinations of the
LDLR ligand-binding domain were aligned with the LDLR tertiary structure
in the database.

Statistical analyses: All data reported were obtained from independent
experiments repeated at least three times. Data were plotted as ±SE of
the mean. P-values were obtained from paired t-test analyses.
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Figures

FIGURE 1. LDLRΔ4-variant mRNA is expressed in brain and liver
of LDLR-/- mice.
End-point PCR was used to identify LDLRΔ4 transcripts. (A) Primers A and
B were designed to anneal 70 bp upstream and 35bp downstream of exon
4, respectively. (B) Amplification of cDNA from NTG and LDLR-/hippocampus, cortex, and liver gave products corresponding to full-length
LDLR (489 bp) or LDLR lacking exon 4 (105 bp).
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FIGURE 2. LDLRΔ4-variant mRNA is expressed in brain and liver
of NTG mice and upregulated in brain and liver of LDLR-/- mice.
Real-time quantitative RT-PCR was used to detect LDLR (A) and LDLRΔ4
(B) mRNA in brain and liver of NTG and LDLR-/- mice. Primer and probe
sets were specifically designed to amplify the exon 4-5 and 3-5
boundaries of cDNA from brain and liver samples. Relative quantitation of
LDLRΔ4 and LDLR were obtained from three independent experiments
using samples from NTG mice (n=5). Trace amounts of LDLRΔ4 signal
were detected above background in brain (C) and liver (D) of NTG mice.
LDLRΔ4 signal between brain and liver of LDLR-/- was p > 0.05.
Student’s t-tests were performed using data from experiments done in
triplicate. ND: not detectable. P-values in the graphs correspond to the
statistical difference between the conditions indicated within the brackets.
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TABLE 1. LDLRΔ4-variant mRNA is upregulated in LDLR-/- mice.
Summary of RT-PCR data from figures 1 and 2.
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FIGURE 3. LDLR-positive protein is present in LDLR-/- brain, but
not liver.
Western blots for LDLR in liver (A) and brain (B) using the anti-LDLR
antibody. Gels were loaded with equal amounts of microsomal proteins.
Actin detection was used as a loading control. (C) Quantitation of the
relative intensity of the LDLR-positive signal in NTG and LDLR-/- brain
samples (n=5; P=0.63). NL: NTG liver; -/-L: LDLR-/- liver.
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FIGURE 4. LDLR signal is present in brain and primary neurons of
LDLR-/- and NTG mice with similar intensity and distribution.
Brain (A) and liver (B) sections of NTG and LDLR-/- mice were immunostained with anti-LDLR antibody, detected with IR Dye 680 goat antirabbit secondary and scanned on the Odyssey Imager. Signal detection
was proportionally inhibited with incubation of the primary antibody with
increasing amounts of rmLDLR (C). (D-H) Sagittal sections of NTG and
LDLR-/- brain and liver were immuno-stained with anti-LDLR antibody.
Representative images of medial cortex (D), hippocampus (E), ventricle
(F), cerebellum (G), and liver (H) are shown. The negative control
samples correspond to staining without primary antibody. (I) Primary
neuronal cultures from NTG and LDLR-/- mice were immuno-stained as
described for panels D-H. rmLDLR: recombinant-mouse LDLR protein.
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FIGURE 5. ApoE binding in LDLR-/- primary neurons via LDLR
protein is conserved.
(A) The seven repeats of the LDLR LBD are aligned to show distribution of
the six cysteine-containing regions in each repeat. The sequence coded
by exon 4 is highlighted in red. (B) The resulting LBD of LDLRΔ4 contains
repeats 1, 2, 6, and 7 of the full-length LDLR. R5 and R2 are the repeats
that flank upstream of R6 in the LDLR and LDLRΔ4 LBD, respectively. (C)
Residues participating in ligand binding (*) and calcium coordination (#)
are shown within the boxes. (D) Schematics derived from ExPASy
indicating the tertiary structures of coupled repeats in the LDLR LBD. (iiv) Tertiary structures of the sequences spanning repeats 2 and 3 (i), 3
and 4 (ii), 4 and 5 (iii), and 5 and 6 (iv) of the LDLR. The last image (v)
corresponds to the sequences of repeat 2 and 6, which is the resulting
apoE-binding region of LDLRΔ4.
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FIGURE 6. Glia-derived apoE co-localizes with LDLR protein on the
plasma membrane and cytoplasm of NTG and LDLR-/- primary
neurons.
Primary neurons from NTG and LDLR-/- mice were incubated with gliaderived apoE. Cells were fixed and immuno-stained for LDLR (red) and
apoE (green). The merged image (yellow) shows potential
staining was used as a nuclear marker.
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FIGURE 7. LDLRΔ4-variant mRNA expression is upregulated in the
PSAPP mouse brain.
LDLR and LDLRΔ4 mRNA expression in NTG and PSAPP brain tissue was
detected by quantitative RT-PCR. (n=5; P-value for LDLRΔ4 is 0.01). Mice
were 11-12 months old, and experiments were done in triplicate.
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TABLE 2. Increased LDLRΔ4 mRNA expression in PSAPP mice.
Summary of RT-PCR data from figure 7.
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LDLR EXPRESSION AND LOCALIZATION ARE ALTERED IN MOUSE AND
HUMAN CELL CULTURE MODELS OF ALZHEIMER’S DISEASE

Abstract

Background: Alzheimer’s disease (AD) is a chronic neurodegenerative
disorder and the most common form of dementia. The major molecular
risk factor for late-onset AD is expression of the ε-4 allele of
apolipoprotein E (apoE), the major cholesterol transporter in the brain.
The low-density lipoprotein receptor (LDLR) has the highest affinity for
apoE and plays an important role in brain cholesterol metabolism.
Methodology/Principal Findings: Using RT-PCR and western blotting
techniques we found that over-expression of APP caused increases in
both LDLR mRNA and protein levels in APP transfected H4 neuroglioma
cells compared to H4 controls. Furthermore, immunohistochemical
experiments showed aberrant localization of LDLR in both H4-APP
neuroglioma cells and in the PSAPP transgenic mouse model of AD.
Finally, these changes were paralleled by and likely the result of a
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disruption

of

the

microtubule-organizing

center

and

associated

microtubule network, as evidenced by immunofluorescent staining of both
γ- and α-tubulin.
Conclusions/Significance: These data suggest that increased APP alters
microtubule function leading to alterations in LDLR location. Consequent
deleterious effects on apoE uptake and function will have implications for
AD pathogenesis and/or progression.
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Introduction

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder
and the most common form of dementia. Currently, almost 50% of the
population over 85 years of age suffers from AD. Onset of the disease
after age 65 is described as late-onset or sporadic AD, which accounts for
over 95% of the cases and has an idiopathic etiology. Extracellular βamyloid deposits in the cores of neuronal (senile) plaques and in vessel
walls, intraneuronal neurofibrillary tangles, and neuroinflammation
characterize the disease’s pathology resulting in accelerated neuron loss
and dementia (Glenner & Wong, 1984). Amyloid deposits are the result of
abnormal processing of the amyloid precursor protein (APP) by two
enzymes: β- and γ-secretase. Mutations in the two presenilin (PS) genes
encoding the catalytic core of γ-secretase as well as mutations in the APP
gene lead to increases or alterations in Aβ, a 38-42 amino acid peptide
and the seed for, and major component of amyloid pathology. The
particular structure of Aβ42, which is the most pathogenic form, confers
the ability to self-aggregate, oligomerize, and, dependent on the
presence apolipoprotein E (apoE), to polymerize into amyloid filaments
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(Mahley, et al., 2006; Potter, et al., 2001; Strittmatter, et al., 1993).

The ε-4 isoform of apoE is the strongest molecular risk factor for
the development of AD. About 60-80% of AD patients have at least one
copy of apoE4 (Mahley, et al., 2006; Saunders, et al., 1993; Strittmatter,
et al., 1993) and the risk for AD is increased in an ε-4 allele dosedependent manner (Corder, et al., 1993). ApoE is a 34 kDa, 299-amino
acid glycoprotein and is the chief cholesterol transporter in the central
nervous system (CNS). It’s gene, located on chromosome 19q13, may
code for any homozygote or heterozygote combination of three common
isoforms, apoE2, apoE3, and apoE4 (Havel & Kane, 1973; Zannis, et al.,
1981). In the CNS, apoE-cholesterol is principally made in astrocytes and
exported to neurons (Boyles, et al., 1985; Elshourbagy, et al., 1985);
however, neurons can also produce apoE-cholesterol during stress (Q.
Xu, et al., 2006). Despite the presence of several receptors that are
capable of internalizing apoE such as low-density lipoprotein receptor
(LDLR), LDLR-related protein (LRP), apoER2, and VLDLR, in neurons apoE
is mostly imported via the LDLR (Innerarity & Mahley, 1978; Innerarity,
et al., 1979; Mahley, 1988; Mahley & Rall, 2000).

LDLR is a membrane-spanning glycoprotein that plays a critical role
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in removing LDL and VLDL from the blood (Goldstein & Brown, 1976;
Sudhof, Goldstein, et al., 1985). Under low intracellular sterol levels,
LDLR gene expression is primarily and directly activated by sterol
response element-binding proteins (SREBPs) (Smith, et al., 1990) and
secondarily by thyroid hormone (Lopez, et al., 2007). The translation of
LDLR mRNA yields a 120 kDa protein that is post-translationally modified
in the Golgi apparatus into the mature, 160 kDa LDLR (Tolleshaug, et al.,
1982; Yamamoto, et al., 1984). The mature receptor can be divided into
five regions: the N-terminal ligand-binding domain (Sudhof, Goldstein, et
al., 1985; Sudhof, Russell, et al., 1985), the epidermal growth factor
precursor homology domain (Davis, Goldstein, et al., 1987; Sudhof,
Russell, et al., 1985), the O-linked polysaccharide domain (Davis, et al.,
1986) where the protein is post-translationally modified, the membranespanning domain (Goldstein, et al., 1985; Lehrman, et al., 1987;
Lehrman, et al., 1985), and the C-terminal cytoplasmic domain
(Goldstein, et al., 1985). Upon maturation, LDLR is transported to the cell
membrane via a clathrin-coated pit vesicle (Davis, van Driel, et al.,
1987). On the membrane, the ligand-binding domain is exposed
extracellularly to associate and internalize LDL or VLDL, mediated by
apoB or apoE, respectively. Once inside the cell, LDLR-ligand-containing
vesicles are acidified by proton pumps (M. S. Brown & Goldstein, 1986),
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leading to uncoupling of the receptor-ligand complex. At this point, the
LDL or VLDL-cholesterol undergoes further processing to be readily
available for the cell’s requirements.

Several groups identified a potential contribution of LDLR to AD and
investigated potential links, for example by crossing AD transgenic mice
with the LDLR-/- mouse model of hypercholesterolemia to investigate the
effects of LDLR deficiency (Blacker, et al., 2003; Cheng, et al., 2005;
Corder, et al., 2006; Gopalraj, et al., 2005; Lamsa, et al., 2008; H. Li, et
al., 2008; Papassotiropoulos, et al., 2005; Retz, et al., 2001; Rodriguez,
et al., 2006; Scacchi, et al., 2001; Wijsman, et al., 2004). Some
apparently opposing results were obtained. Here we investigate the
effects of APP over-expression on the expression and localization of LDLR
to identify possible changes that could result in an altered apoE
metabolism. We report that over-expression of APP in a human
neuroglioma cell line increased the amounts of LDLR mRNA and protein,
and the receptor accumulated in the perinuclear region of the APPexpressing cells. This altered localization was specific to LDLR and could
not be seen for LRP. Furthermore, in comparing NTG with PSAPP and
APP-/- transgenic mouse models, we found that LDLR protein levels were
directly proportional to the amount of APP. Immunohistochemical analysis
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of α- and γ-tubulin suggest that alterations in LDLR are rooted in an APPmediated disturbance of the centrosome and microtubules, preventing
proper transport of LDLR to the plasma membrane.
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Results

Initially, we sought to determine changes in the mRNA and protein
levels of LDLR in human neuroglioma cells that were stably transfected
with human wild-type APP (H4-APP) and used their non-transfected H4
counterpart as controls. H4-APP cells express about 12 times more APP
than non-transfected controls and it is distributed throughout the whole
cell (Supplemental Figure S1). RT-PCR experiments with H4 and H4-APP
cells demonstrated a 3-fold increase in LDLR mRNA in H4-APP cells
compared to H4 controls (Figure 1A). This result was paralleled at the
protein level as evidenced by western blot analysis (Figure 1B).
Quantification of the immunoblots showed a 4-fold increase in LDLR
protein in H4-APP cells compared to H4 controls (Figure 1C).

Next, we performed immunofluorescence imaging on H4 and H4APP cells to determine changes in LDLR localization. In order to assess
whether potential APP-induced alterations were specific to LDLR, we
immunostained for LDLR and another member of the LDLR family, LRP
(LDLR-related protein-1) (Figure 2A). Images of H4 and H4-APP cells
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without primary antibody incubation are shown as a negative control of
the assay (Figure 2A). While we did not observe significant changes in
the distribution of LRP, we found that in H4-APP cells, LDLR had become
densely concentrated in the perinuclear region (indicated by the
arrowheads in panels 2A and 2B). Compared to LDLR localization, the LRP
signal was concentrated in a perinuclear density in both H4 and H4-APP
cells. At closer inspection (Figure 2B), we confirmed that in H4 control
cells, LDLR is homogeneously distributed, whereas in H4-APP cells, LDLR
appears to converge to form a dense perinuclear core. To quantifify this
effect, we defined cells displaying a dense LDLR-positive focus as cells
containing a signal that was three standard deviations above the
background and with at least 1000 pixels2. By this criterion, 59% of H4APP versus 10% of H4 cells had LDLR accumulated in the perinuclear
zone of the cells. (Figure 2C; *p = 0.001). In contrast, 72% of H4-APP
cells and 66% of H4 cells displayed the dense perinuclear signal for LRP,
not indicating any significant change (Figure 2D; p = 0.56).

It seems reasonable that if LDLR becomes highly concentrated in a
single perinuclear core, then there may be a relative deficit of LDLR in its
normal, physiologically relevant location on the plasma membrane. We
therefore examined H4 and H4-APP cells with the LDLR antibody as
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above, but leaving out the permeabilization step so as to only visualize
cell-surface LDLR. H4-APP cells exhibited a 32% significant reduction of
plasma membrane-associated LDLR (Figure 3A, 3B, and 3C). This result
indicated that there was likely a concomitant reduction in LDLR function,
despite the compensatory upregulation of LDLR mRNA and protein shown
in Figure 1.

AD pathology is initiated and maintained when the APP protein
becomes proteolytically cleaved to generate various forms of the Aβ
peptide, the 1-42 amino acid version being one of the most pathogenic.
In order to assess the general relevance of the redistribution of the LDLR
in H4-APP cells, we repeated the experiment using cultured mouse
cortical neurons from normal mice and exposing them to 1uM of either
Aβ40 or Aβ42 for 48 hours; as a reference, we also treated and
immunostained a set of neurons with a peptide consisting of scrambled
amino acids of the Aβ42 peptide (Figure 4A and 4B). Similar to the H4-APP
cells, the Aβ40- and Aβ42-treated cortical neurons had 23% (*p < 0.05)
and 13% (**p < 0.01) less surface LDLR compared to Aβ42 scrambled
peptide-treated cells (Figure 4C). The amount of surface LDLR was also
significantly decreased in Aβ40-treated compared to Aβ42-treated cells
(10%; *p < 0.05).
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Thus far we have shown that the upregulated LDLR protein in H4APP cells cannot be accounted for on their cell membrane. To identify the
localization of the LDLR aggregate, we co-stained LDLR with organelle
markers for the Golgi apparatus (Figure 5A and 5B), lysosomes (Figure
5C and 5D), endoplasmic reticulum (Figure 5E and 5F), and early
endosomes (Figure 5G and 5H). We found that in H4-APP cells, LDLR
signal co-localized in the Golgi apparatus and lysosomes, or the transGolgi network. In contrast, LDLR signal in the ER or endosomes was not
particular to either H4 or H4-APP cells.

We next sought to reproduce the APP-induced LDLR overexpression and mis-localization in a physiologically relevant experimental
system—an in vivo model of AD. We chose PS1+/-APP+/- (PSAPP) mice
at 10 months of age when their brains are burdened with amyloid,
homogenized brain tissue from the PSAPP mice and age-matched nontransgenic (NTG) controls and performed western blot analysis for LDLR.
We observed a modest, yet significant increase of LDLR in PSAPP mice
compared to controls (Figure 6A and 6B; 20% increase with *p = 0.05).
The same experiment served to confirm that the PSAPP mice
overexpressed APP (Figure 6A). In order to further investigate whether
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the LDLR protein levels are influenced by APP expression, we performed
western blots for LDLR in 10-month old APP-/- mice. Interestingly, we
found that LDLR was decreased by 55% in these mice compared to agematched controls (Figure 6C and 6D; *p = 0.04). These experiments
indicate that LDLR expression directly correlates with APP expression.

To determine if changes in LDLR expression are paralleled by
changes

in

its

localization

in

PSAPP

mice,

we

performed

immunohistochemistry on brain tissue sections of PSAPP mice of 10
months and age-matched controls. We detected an increase in the LDLR
signal in the hippocampus of PSAPP mice, a region that is particularly
affected by the amyloid pathology. This effect was the strongest in the
CA3 region of the hippocampus (Figure 7A). At higher magnification, we
found that cells surrounding the neuronal layer of the hippocampus in
PSAPP tissues also showed a dense accumulation of LDLR similar to that
observed in H4-APP cells (arrowhead in PSAPP hippocampal cell of figure
7A), whereas the NTG counterpart lacked that same signal concentration
(Figure 7A). After quantification of the LDLR signal normalized to the
amount of DAPI signal in each field, we calculated a 30% increase (*p =
0.04) in LDLR in the hippocampi of PSAPP mice compared to NTG controls
(Figure 7B).
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The centrosome, or microtubule-organizing center (MTOC), is
responsible for the nucleation step preceding the polymerization of
microtubules and maintains the structure of the microtubule network. It
was previously reported that PS1 and APP bind to the centrosome (J. Li,
Xu, Zhou, Ma, & Potter, 1997; Nizzari, et al., 2007). We therefore
reasoned that the mechanism behind the changes in localization and
expression levels of LDLR mRNA and protein could be based on an APPmediated alteration of the microtubule-trafficking system. To address this
hypothesis, we performed immunohistochemistry in H4 and H4-APP cells
targeting γ-tubulin as a marker of the MTOC. While we observed
condensed staining of γ-tubulin in H4 cells, H4-APP cells showed a diffuse,
non-nuclear pattern of γ-tubulin signal (Figure 8A and 8B) where 0.64%
of the γ-tubulin signal was dispersed in H4-APP cell. In contrast, 0.72%
percent of the γ-tubulin signal was diffuse in the H4 cells; this was a
modest change (0.08%), yet it was significantly different (*p = 0.01;
Figure 8C).

Finally, to address the relationship between APP over-expression
and alterations to the mature microtubule-trafficking network, we
performed immunofluorescent staining of H4 and H4-APP cells targeting
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α-tubulin as an indicator of microtubule localization. We found that only
82% of the alpha-tubulin signal in H4-APP cells was diffuse, while H4 cells
had 87% of the total α-tubulin signal spread throughout the cell (Figure
9A and 9B). Like in the γ-tubulin staining experiment, this was a modest
but significant change in signal distribution (5%; *p = 0.04) between the
transgenic and non-transgenic (Figure 9C).
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Discussion

Characterization of apoE metabolism in the brain is of critical
importance for the development of potential therapeutic targets for AD.
Because apoE is the principal ligand for LDLR, alterations to LDLR
trafficking are likely to impact AD pathology as well. As the main
cholesterol transporter in the CNS, apoE is produced by glia and delivers
cholesterol cargo to neurons by receptor-mediated endocytosis via LDLR.
In order for apoE-cholesterol to enter the cell, LDLR must be localized to
the plasma membrane. Our findings indicate that in H4-APP cells and
primary neurons treated with Aβ, this localization is altered in that there
is a significant decrease in the amount of cell surface LDLR (Figure 3 and
4). As, transcriptional activation of the LDLR gene is normally induced by
a system that is sensitive to low levels of intracellular sterols (Smith, et
al., 1990), it seems likely that the upregulation of LDLR (Figure 1)
indicates that the H4-APP cells are cholesterol starved due to nonfunctional localization of LDLR.

Dietary and endogenous biosynthesis of cholesterol modulates the
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rate at which APP is processed into Aβ. Studies using animals fed high
cholesterol diets revealed an increase in amyloid plaque formation in
rabbits and in transgenic mouse models of AD (Howland, et al., 1998;
Shie, et al., 2002; Sparks, et al., 1994); moreover, in these mice, the
high cholesterol diet induced cognitive decline (Thirumangalakudi, et al.,
2008). In vitro studies show that imbalances in cellular cholesterol may
favor APP cleavage by either α- or γ-secretase. Conversely, cholesteroldepleted rat hippocampal primary neurons show reduced APP processing
into Aβ (Fassbender, et al., 2001; M. Simons, et al., 1998) and favor the
generation of non-amyloidogenic APP processing by α-secretase to yield
the soluble, non-pathogenic protein sAPPα (Bodovitz & Klein, 1996;
Kojro, et al., 2001). In contrast, γ-secretase processing is favored when
APP is located in the lipid raft; the result is formation of toxic Aβ peptide.
Thus, the amount and distribution of cellular cholesterol is essential for
the formation of lipid rafts, and therefore the localization and processing
of APP. This connection might also mean that if the observed increased
expression of LDLR in apparent compensation for incorrect localization
induced by APP overshoots, then more apoE-cholesterol could be
imported, leading to more APP processing to Aβ in an accelerating
pathogenic cycle.
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Our experiments on PSAPP mice show that LDLR and APP protein
levels are directly proportional (Figure 3). These results together with
those obtained with the H4 and H4-APP cell models suggest that APP
over-expression affects the MTOC such that LDLR transport to the cell
membrane is significantly abrogated. Consequently, net cholesterol
import into the cell is decreased, leading to upregulation of LDLR
transcription and protein levels. It was previously shown that APP and
PS1 bind to the centrosome (J. Li, et al., 1997; Nizzari, et al., 2007). As a
result, the centrosome’s nucleation function for microtubule formation
may be disrupted by association with excess levels of APP or Aβ in our
over-expression models or by mutations of the APP gene. This in turn
may have widespread detrimental effects for the entire microtubule
trafficking system. Our results provide evidence that trafficking of other
proteins, organelles, or vesicles in the cell may also be disturbed,
although this cannot be true for all proteins as LRP localization was
unchanged in the H4-APP cells. (Figure 2A).

Over the past 15 years, a considerable amount of effort has been
dedicated to characterize the potential participation of LDLR in AD
pathology. This interest is based on data procured from linkage analyses
of AD risk and the LDLR gene, preliminary data from population and case156

control studies, and the importance of LDLR function in the regulation of
cholesterol homeostasis via apoE metabolism, whose e4 allele is the most
important risk factor for ‘sporadic’ AD besides age. Linkage analyses were
based on the fact that the LDLR gene locus and a region associated with
high frequency of AD risk share a common location on chromosome 19
(Blacker, et al., 2003; Wijsman, et al., 2004). Furthermore, this peak of
risk for AD onset is independent of the risk imparted by the nearby apoE4
gene (Wijsman, et al., 2004). Consequent attempts to characterize
linkage of LDLR and AD onset yielded at least ten, case-control
association studies and one family-based study (Cheng, et al., 2005;
Corder, et al., 2006; Gopalraj, et al., 2005; Lamsa, et al., 2008; Lendon,
et al., 1997; H. Li, et al., 2008; Papassotiropoulos, et al., 2005; Retz, et
al., 2001; Rodriguez, et al., 2006; Scacchi, et al., 2001; Zou, et al.,
2008). Of particular interest were polymorphisms contained in exons 8,
10, 13, and 15, as they had been proposed to have associations with risk
of AD onset (Cheng, et al., 2005; Gopalraj, et al., 2005; Retz, et al.,
2001). The overall conclusion of these studies is, however, still
developing.

Other conflicting reports have investigated LDLR’s participation in
AD at the molecular level (Cao, et al., 2006; Fryer, et al., 2005;
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Thirumangalakudi, et al., 2008). The objective of these studies was to
study whether elimination of LDLR expression would affect the pathology
in AD mice. To this end Fryer et. al. (Fryer, et al., 2005) and Cao et. al.
(Cao, et al., 2006) crossed the LDLR-/- mouse with mouse models of AD:
the PDAPP and Tg2576, respectively. Both groups agreed that LDLR is the
main regulator of apoE in CNS as they observed a significant increase in
apoE levels in the CNS of their mice. However, Fryer et. al. did not
observe changes in pathology, whereas Cao et. al. reported a mild yet
significant increase in plaque deposition. Furthermore, this latter study
also reported that the mice performed poorly on a battery of cognitive
tests. The question of whether LDLR is involved in AD pathogenesis
and/or progression remains unanswered.

In contrast to the investigations of the role of LDLR in AD, our
approach was to determine instead the effects of amyloid pathology on
LDLR metabolism. We describe in this report that APP/Aβ over-expression
causes alterations to LDLR that may be explained by an APP/Aβ-mediated
effect on the microtubule trafficking system. In H4-APP cells, a human
neuroglioma cell line stably over-expressing human wild-type APP, LDLR
mRNA and protein levels are increased. In these conditions, H4-APP had
LDLR aggregated in the trans-Golgi network, which precluded its
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trafficking to the cell membrane. Furthermore, Aβ treatment also caused
aggregation of the LDLR signal. Concomitantly, the PSAPP mouse model
of AD, which over-expresses the full-length human APP containing the
V717F mutation, also shows aberrant distribution and a mild, yet
significant increase in LDLR protein. The experiments suggest that a likely
explanation for these phenomena is that H4-APP cells have changes in
the localization of the microtubule proteins α- and γ-tubulin.

The H4-APP cells and PSAPP mouse models we evaluated emulate
the APP-induced amyloidogenic effects seen in individuals with trisomy
21. Interestingly, the serum cholesterol and lipid profiles of these
individuals are abnormal, yet they are protected against atherosclerosis
(Murdoch, Rodger, Rao, Fletcher, & Dunnigan, 1977; Yla-Herttuala,
Luoma, Nikkari, & Kivimaki, 1989). It would be interesting to assess
whether LDLR turnover rates are changed in different tissues of
individuals with trisomy 21.

Based on our data, we suggest that, rather than a precursor, DS
and AD dyslipidemia is a consequence of AD-like amyloid pathology
induced by increased APP. We propose that rescuing the LDLR transport
to the cell membrane would provide benefit to AD patients. Furthermore,
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careful evaluation of the mechanisms underlying APP processing as a
factor in cholesterol metabolism may yield novel therapeutic targets
against Alzheimer’s.
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Materials and Methods

Materials: Quantitative-PCR experiments were performed using Applied
Biosystems, PCR master mixes, human GAPDH endogenous control
assays, and gene expression assays for human LDLR (assay ID
Hs01092525_m1). Tissue culture reagents and electrophoresis supplies
were purchased from Gibco/Invitrogen. Protein concentrations were
determined with BCATM (Pierce) colorimetric assays. Aβ peptides were
obtained from American Peptide.

Antibodies: Rabbit anti-LDLR antiserum was a generous gift from Dr.
Joachim Herz at the University of Texas Southwestern. It was used as
primary antibody for immunoblots (1:1000) and immunohistochemistry
assays (1:100) (Ishibashi, et al., 1993). Alternatively, a monoclonal antiLDLR antibody from Fitzgerald Industries International (cat.# 10-L55A)
was used for immunohistochemistry experiments where the co-stain
targets required rabbit-polyclonal antibodies. Organelle markers for the
Golgi apparatus, lysosomes, and early endosomes (GM130, LAMP1, and
EEA1 antibodies, respectively) were purchased from Cell Signaling
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Technologies, while the KDEL antibody, a marker of endoplasmic
reticulum was purchased from Stressgen. Monoclonal mouse anti-actin
(Sigma-Aldrich) and AlexaFluor 488 and 594 (Invitrogen/Molecular
Probes) antibodies were diluted according to the manufacturer for
western blot (WB) and immunohistochemistry (IHC) assays, respectively.
Goat anti-mouse IRDye®800CW and goat anti-rabbit IRDye®680 were
purchased from LI-COR Biosciences (WB: 1:15,000; IHC: 1:1500).
Monoclonal anti-α-tubulin and γ-tubulin antibodies were obtained from
Sigma-Aldrich and diluted according to the company’s specifications.
Anti-LRP antibody was a generous gift from Dr. Guojun Bu.

Animals: All procedures involving experimentation on animal subjects
were done in accord with the guidelines set forth by the University of
South Florida’s Institutional Animal Care and Use Committee (IACUC).
Mice with the genotype APP+/-, PS1+/- were generated by crossing
heterozygous PDGF-hAPP(V717F) mice [Swiss-Webster X C57BL/6] with
PDGF-hPS1(M146L) heterozygotes [Swiss-Webster X C57BL/6] as
described (Costa, et al., 2007). Non-transgenic (NTG) control mice for
LDLR-/- mice were C57BL/6J expressing endogenous LDLR (The Jackson
Laboratory). NTG control mice for APP+/-, PS1+/- were littermates that
lacked both transgenes. All mice were genotyped by PCR to confirm the
162

presence or absence of PDGF-hAPP (Games, et al., 1995) and PDGF-hPS1
(Duff, et al., 1996). APP knock-out mice (strain B6.129S7-APPtm1Dbo/J)
were obtained from The Jackson Laboratory and were genotyped
according to the provider’s recommendations. Primary neurons were
obtained from the cortex and hippocampus of E18 NTG mice as described
(Padmanabhan, et al., 2006). Neurons were grown for one week on polyL-lysine-coated 8-chamber slides in neurobasal medium with B27
supplement. Neurons were then treated for 48 hours with 1 µM
concentration of either Aβ40 or Aβ42. Cells were then fixed and stained as
described below in the immunohistochemistry section.

Tissue preparation: Brain tissue was acquired by anesthetizing mice with
0.1 mg/g Nembutal followed by transcardial perfusion with 0.9% saline
solution for 8-12 min at 120 mmHg. Whole brains were immediately
removed for processing. Messenger RNA was extracted by homogenizing
tissues in TRI reagent (Sigma-Aldrich). Microsomal protein extracts were
obtained as previously described (Ness, et al., 1986), with minor
modifications: 0.25M sucrose was prepared with protease inhibitors (1
tablet mini-Complete/ 10 ml sucrose, Roche Applied Science). Samples
were dounce homogenized and spun at 10,000 x g for 10 min. Then,
supernatants were spun once at 30,000 x g for 90 min in a fixed-angle
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rotor. Microsome pellets were resuspended in PBS with 10% glycerol and
protease inhibitor cocktail (Roche). Brains for immunohistochemistry
assays were fixed for 24 hrs in 4% para-formaldehyde. The fixed tissues
were cryo-protected in successive sucrose gradients as previously
described (Nilsson, et al., 2001). Brains were frozen on a temperaturecontrolled freezing stage, coronally sectioned (25 µm) on a sliding
microtome, and stored in a solution of PBS containing 0.02% NaN3 at
4oC.

Quantitative RT-PCR: Five micrograms of DNase-treated mRNA were
reverse-transcribed with SuperScript® VILOTM cDNA Synthesis Kit
(Invitrogen) using random hexamers according to the manufacturer’s
instructions. Quantitative RT-PCR was performed according to the
manufacturer. Reactions were processed in the 7500 FAST System with
its Sequence Detection Software (SDS) from Applied Biosystems.

Western blots: Unless otherwise indicated, 50 µg (protein) of brain
microsomes, were denatured with LDS sample buffer according to the
Invitrogen protocol. Samples were loaded onto 3-8%, 1.0 or 1.5mm TrisAcetate gels, and run at 80V for 180 min. Gels were dry- (iBlot,
Invitrogen) or wet-transferred onto PVDF membranes for 9 min. Non164

specific protein binding to the membrane was blocked by incubating with
5% BSA or 7% non-fat dry milk for 90 min at room temperature. Primary
antibody for actin was diluted 1:10000, while LDLR antibodies were
diluted 1:1000 in blocking buffer and incubated overnight at 4°C.
Secondary antibody incubations with either IR-dyes (1:15000) or HRPconjugated were performed sequentially for 60 min at room temperature.
Membranes were washed three times for 10 min with PBS or TBS and
0.1% Tween-20 after incubation with each antibody. Membranes were
scanned and analyzed with the LI-COR Odyssey and accompanying
software or developed using ECL reagent.

Immunohistochemistry: H4 and H4-APP cells were cultured in 8-chamber
slides for 3 days prior to immunostaining. Cells were then fixed in icecold methanol or 4% para-formaldehyde for 15 min at room temperature
and incubated with blocking buffer (described below). Brain sections were
mounted onto Colorfrost®/Plus slides (Fisher Scientific) Non-specific
binding was blocked in NGS (10% normal goat serum, 0.2% Triton X100, and 0.02% NaN3 in Tris-buffered saline (TBS)) or in NGS without
detergents for non-permeabilizing experiments, for 120 min at room
temperature. Primary antibodies were incubated overnight at 4°C in 10%
NGS. After four, 5 min washes in TBS, slides were incubated with
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AlexaFluor -594 and -488 (anti-rabbit and anti-mouse, respectively)
secondary antibodies in 10% NGS for 60 min at room temperature and
washed in TBS. Slides were stained with Hoechst (1µg/ml in PBS) for 2
min to reveal cellular nuclei and mounted using GelMount (Fisher
Scientific). Staining was analyzed with the Zeiss AxioImager.Z1 and
AxioVision software using 5x/0.16 or 40x/0.75 dry ECPlan-NeoFluor
objectives where specified. Images were captured at room temperature
with an AxioCam MR3 camera. Fluorochromes used were DAPI, DsRed,
and FITC. The magnified hippocampal cell image in figure 4A was
modified in Adobe Photoshop by changing the brightness and contrast to
both the NTG and PSAPP cell images equally and simultaneously.

Image quantification: LDLR, LRP, γ and α-tubulins, and APP were
quantified using ImageJ as described in Figure S2. Analysis of figures 3
and 4 were performed by the following procedure: images scanning the
entire wells for H4, H4-APP, and no-primary-antibody negative controls
were obtained. These images were taken at 100x and using the same
exposure time for the channel corresponding to LDLR. We discarded
pictures containing artifacts (such as those with cells damaged by the
pipette tip), images from the edges of the wells (due to potential artifacts
caused by the rubber gasket), and fields containing less than 200 nuclei.
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We obtained the integrated density (I.D.) of each field and the number of
cell nuclei using ImageJ (Abramoff, 2004; Rasband, 1997-2009). We
divided the I.D. by the number of cell nuclei to generate the amount of
plasma membrane LDLR/cell (I.D./cell). The I.D./cell for the negative
control was subtracted from the I.D./cell of H4 and H4-APP cells. The
average of the values for each condition was compared.

Statistical analyses: All data reported were obtained from independent
experiments. Data were plotted as ±SE of the mean. P-values were
obtained from paired t-test analyses.
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Figures

Figure 1. LDLR mRNA and protein are upregulated in H4-APP cells
compared to H4 controls.
(A) RT-PCR quantification of LDLR mRNA expression level in H4 and H4APP cells (n = 3; *p = 0.04). LDLR threshold cycle values were
normalized to GAPDH. (B) Western blot for LDLR in whole-cell lysates
from H4 and H4-APP cells. Lane 1 contains liver whole-cell lysate from a
NTG mouse. (C) Quantification of western blot (n = 3; *p = 0.01). All
bands for LDLR were quantified and their values shown in this graph. The
LDLR band densities were normalized to the actin band in each lane. RTPCR and western blot experiments were conducted in triplicate.
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Figure 2. LDLR distribution is altered in H4-APP cells compared to
H4 controls.
(A) Immunohistochemistry imaging at 400x magnification of LDLR and
LRP in H4 and H4-APP cells. Red signal corresponds to LDLR or LRP as
indicated and blue signal corresponds to Hoechst-labeled cell nuclei.
Arrowheads point to three examples of a dense perinuclear LDLR-positive
signal present in H4-APP cells. (B) Larger image of a selected cell from
panel 2A; the arrowhead points to an LDLR-positive density. (C and D)
Quantification of the percentage of cells with perinuclear density of
fluorescent signal in LDLR (C) and LRP (D), which is described in more
detail in supplemental figure 2.
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Figure 3. Surface LDLR is reduced in H4-APP cells compared to H4
controls.
H4 and H4-APP cells were immunostained for LDLR in the absence of
detergents to prevent permeabilization of the plasma membrane. (A)
Images magnified at 400x showing LDLR signal (red) and nuclei (blue)
for H4 and H4-APP. (B) Zoomed image of one cell isolated from panel A.
(C) Quantification of the average LDLR-positive signal per cell showing a
32% reduction of LDLR on the membrane of H4-APP cells (*p = 0.03).
The average of the ratio of the total LDLR intensity and the number of
cell nuclei for the H4 condition was equaled to 100%. The H4-APP ratio
was divided by the H4 ratio of LDLR intensity per cell; A total of ~18,000
cells were taken into account from three independent experiments.
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Figure 4. Aβ 42 alters LDLR localization in primary neurons of NTG
mice.
Primary neurons were obtained from E18 fetuses, plated and grown for
one week, and treated with 1 µM Aβ40 or Aβ42 for 48 hours. Cell surface
LDLR was immunostained (red). (A) Image of primary neurons from cells
treated for 48 hours with 1µM Aβ42 scrambled peptide (as positive
control), Aβ40, and Aβ42; image is magnified 630x. (B) Zoomed image
isolating one cell in each field of panel A.

The negative control

corresponds to staining in the absence of primary antibody.
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FIGURE 5. LDLR is abundant in the trans-Golgi network of H4-APP
cells.
H4 and H4-APP cells were co-stained for LDLR and different organelle
markers. A and B show Golgi apparatus at low and high magnification,
respectively. C and D show LDLR co-stained with lysosomal marker at low
and high magnification, respectively. E and F show LDLR co-stained for
endosomes at low and high magnification respectively. G and H show
LDLR

co-stained

with

endoplasmic

reticulum

at

low

and

high

magnification, respectively. A, C, E, and G were taken at 400x, while B,
D, F, and H are zoomed images.
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Figure 6. Brain LDLR is increased in PSAPP mice and decreased in
APP-/- mice compared to controls.
Whole-cell lysates were prepared from brains of 10-month old PSAPP,
APP-/-, and age-matched non-transgenic control mice for western blot
analyses; liver whole cell lysates were prepared from NTG and LDLR-/- as
positive and negative control homogenates, respectively. (A) Western
blot for LDLR, APP, and actin from PSAPP and NTG control lysates. (B)
Quantification of LDLR signal normalized to actin in western blot of panel
A (n = 5; *p = 0.05). (C) Western blot for LDLR and actin from NTG and
APP-/- mice. (D) Quantification of LDLR signal normalized to actin in
western blot of panel C (nNTG = 3 and nAPP-/- = 4; *p = 0.04).
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Figure 7. LDLR is increased and delocalized in the hippocampus of
PSAPP mice compared to NTG controls.
(A) Representative images at 5x magnification of immunohistochemistry
staining of the CA3 region of the hippocampus and an enlarged view of a
representative hippocampal cell surrounding the neuronal layer of a
PSAPP and NTG mouse. Mice were 10-month old PSAPP and NTG. LDLR
signal is in red and cell nuclei are in blue. Arrowhead in PSAPP
hippocampal neuron indicates the concentration LDLR-positive signal. (B)
Quantification of LDLR-positive signal normalized by the DAPI signal in
hippocampus of PSAPP and NTG mice. Experiments were done in
triplicate using brain sections of 8 mice for each condition.
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Figure 8. γ-tubulin signal is more widely distributed in H4-APP
cells compared to H4 controls.
(A) Immunohistochemistry imaging at 400x magnification of LDLR and γtubulin in H4 and H4-APP cells. Red, green, and blue signals correspond
to LDLR, γ-tubulin, and cell nuclei, respectively. Arrowheads indicate
three examples of H4-APP cells containing greater area of γ-tubulin signal
distribution. (B) Larger image of a selected cell from the same slide.
Merged images in A and B show the location of LDLR in relation to γtubulin and the nucleus. (C) Percentage of diffuse γ-tubulin signal in H4
compared to H4-APP cells. Quantification is described in further detail in
supplemental figure 2.
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Figure 9. α-tubulin is less widely distributed in H4-APP cells
compared to H4 controls.
(A) Immunohistochemistry imaging at 400x magnification of LDLR and αtubulin in H4 and H4-APP cells. Red, green, and blue signals correspond
to LDLR, α-tubulin, and cell nuclei, respectively. Arrowheads indicate
three examples of H4-APP cells containing less diffuse α-tubulin. (B)
Larger images of selected cells from panel A. Merged images in A and B
show the location of LDLR in relation to α-tubulin and the nucleus. (C)
Percentage of diffuse α-tubulin signal in H4 compared to H4-APP cells.
Quantification is described in further detail in supplemental figure 2.
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Figure 10. Proposed mechanism by which APP/Aβ overexpression
diminishes LDLR trafficking by disrupting microtubule formation.
Overexpression of APP/Aβ causes microtubule destabilization by altering
the centrosome, and consequently, polymerized microtubules. As a
result, LDLR trafficking from the TGN to the plasma membrane is
impaired. Therefore, LDLR accumulates in the TGN. The implications are
that the cell is unable to import cholesterol effectively, which causes
transcriptional activation of the LDLR gene.
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Supplemental figure 1. APP overexpression in H4-APP cells
causes aberrant localization in the cell.
(A) Immunohistochemistry imaging at 400x magnification of LDLR and
APP in H4 and H4-APP cells. Red, green, and blue signals correspond to
LDLR, APP, and cell nuclei, respectively. (B) Quantification graph of
diffuse APP signal between H4 and H4-APP cells. (C) Western blot of APP
in H4 vs. H4-APP cells; actin was used as a loading control. (D)
Quantification of western blot in (C); quantification is described in more
detail in supplemental figure 2.
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Supplemental figure 2. Quantification of staining using Image J.
(A) Representative image of H4 APP cells for analysis. The cells have
been stained for LDLR. (B) Histogram generated from ImageJ based on
the image shown in panel A. Pixel gray value is the color of the pixel on a
scale of 0 to 255, with 0 being absolute black and 255 being absolute
white. (C) Magnification of the histogram in panel B. In this
representative histogram, the mean pixel value is 11.801, and the
standard deviation of the histogram is 23.217. In order to identify the
intensely stained perinuclear density, the image was thresholded at 3
standard deviations from the mean. At this threshold, only pixels with a
gray value of 81 or greater were identified as positive stain (dark gray
region in right tail). Identification of total cellular staining was done with
the image thresholded at 0.5 standard deviations from the mean of the
image, so all pixels with a value of 21 or greater were identified as
positive stain (light gray region and dark gray region). For tubulin
staining, staining outside of the density was defined as that falling
between 0.5 standard deviations and 3 standard deviations (light gray
region only). D) Image showing thresholding of the image shown in panel
A at 3 standard deviations. Note that only intense staining is identified at
this threshold. E) Further identification of the intense perinuclear density
based on the criterion that the region be at least 1000 square pixels in
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area. F K) Representative image of H4 cells stained for LDLR,
thresholded, and perinuclear densities identified as described in A E.
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DISCUSSION

The novel contributions of the work presented in this dissertation
encompass the study of LDLR in the pathogenesis and progression of AD
from two different perspectives: (1) evaluation of the adequacy of the
LDLR-/- model for the study of AD, and (2) investigation of the effects of
APP/Aβ overexpression on LDLR. Initially, the literature on LDLR and AD
shows significant contradictions. We do not argue that these data are
erred, rather that their differences are the consequence of the methods
employed. In population studies, we suspect that the genetic makeup
inherent to the different populations studied by the authors of these
reports contains SNPs that can attribute unique differences in the LDLR
structure and function. Moreover, different environmental pressures may
also play a role in unmasking risk of disease processes by LDLR. These
differences may not be significant to the normal LDLR function in
regulating serum cholesterol. Yet, they may affect LDLR-mediated
processes in the CNS. Seemingly miniscule changes to LDLR function
could suffice to contribute to disease. The end result could be that each
region and population may have unique etiological processes of AD
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pathogenesis. This suspicion becomes more valid when considering that
AD is likely to be the product of multiple contributing sources, as it is to
be expected of diseases of aging where genetic etiologies are only one
contributing factor.

Previous efforts undertaking the study of LDLR and AD, specifically
projects that used the LDLR-/- mouse to characterize its effect in the
CNS, are very valuable. However, our results suggest that the LDLR-/mouse may be inadequate for studying the effects of the absence of LDLR
in the CNS. Therefore, and particularly in the area of AD, the PDAPP x
LDLR-/- and Tg2576 x LDLR-/- mouse models are not suitable for
determining whether the lack of LDLR may prevent, stave off, or worsen
the disease process (Cao, et al., 2006; Fryer, et al., 2005). Instead, the
data reported by these groups reveal important information about the
mice themselves irrespective of LDLR-mediated binding of apoE.

The two major conclusions of these separate studies are that lack
of LDLR had no effect in the AD process and that the lack of LDLR
increased AD pathology and cognitive decline. In 2006, soon after these
conflicting results were published, Tveten et. al. reported having
identified two novel splice-variants of LDLR (Tveten, et al., 2006). One of
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them, the LDLRΔ4, was of interest to us because the knockout scheme for
the LDLR-/- mouse used exon 4 as part of the knockout strategy.
Specifically, Ishibashi et. al. inserted a neomycin cassette within exon 4;
the cassette codes for a poly-adenylation site at the 3’ end of its
sequence (Ishibashi, et al., 1993). As a result, transcription of the LDLR
is incomplete, and generates a truncated LDLR that lacks its intramembranous sequence and therefore it cannot be incorporated into a
vesicle for transport to the plasma membrane.

We hypothesized that exon 4 skipping during transcription would
bypass the poly-A site and continue transcribing exons 5-18. Indeed,
after RT-PCR analyses, we discovered that the LDLR-/- mouse was
capable of producing LDLR mRNA lacking the exon 4 sequence. We
confirmed these results by sequencing the cDNA obtained from the mice.
Quantification

of

LDLRΔ4

mRNA

levels

revealed

transcriptional

upregulation of the splice-variant suggestive of a compensatory
mechanism. This finding is provocative as it discovers a phenomenon that
poses an obstacle for the generation of transgenic, knockout mice.

The next step was to determine if the splice variant generated a
functional protein. Consequently, we tested a total of 14 antibodies as a
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means of identifying LDLRΔ4 protein. In western blotting experiments,
most antibodies detected many non-specific bands, which made it difficult
to confirm that a band located at the predicted molecular weight for
LDLRΔ4 could in fact be this protein. Other antibodies were effective at
detecting LDLR in liver, but fell short in brain homogenates, where
western blots showed no bands. We suspect that the problem arises
because the region coded by exon 4 is not immunogenic and LDLR
expression is very low in the CNS. In 1987, Brown and Goldstein
encountered

similar

problems

in

rabbits:

“Several

attempts

to

demonstrate the presence of LDL receptors in rabbit brain and spinal cord
were unsuccessful because of the lack of high affinity antibody that
recognizes the rabbit LDL receptor and the large amounts of myelin that
limited recovery of the membrane proteins” (Hofmann, Russell,
Goldstein, & Brown, 1987). They turned to the bovine brain as a means
to recover a larger fraction of membrane proteins and successfully
detected LDLR. The difficulty of detecting LDLR in brain led us to try a
proteomic approach. We tried to separate LDLR and LDLRΔ4 by running
brain and liver homogenates of both NTG and LDLR-/- mice on a gel and
staining with Coomassie blue. We used mass spectroscopy and
sequenced a total of 12 bands and were unable to detect either form of
LDLR. We then enriched the amount of these LDLR/LDLRΔ4 by performing
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an immuno-precipitation. Again, the data coincided with neither LDLR nor
LDLRΔ4 sequences. Finally, since the isoelectric points of the full-length
LDLR and the predicted exon 4-lacking variant differ sufficiently (~4.7 to
~7.8) we separated them using 2D-gels.

We were fortunate to have received a polyclonal rabbit antibody
from Dr. Joachim Herz (Russell, et al., 1984). This antibody gave clear
bands from brain and liver samples of NTG mice in western blots at the
expected molecular weight of LDLR. Furthermore, in LDLR-/- brain
microsomal protein preparations, the Herz antibody revealed bands at a
slightly lower molecular weight for LDLR (shown in Chapter 2). We
interpreted this result as the detection of LDLRΔ4. It is critical to note
that the lack of a specific antibody for LDLRΔ4 limited the confirmation of
the ability of the cell to make this protein. However, despite this caveat,
we felt confident that the most likely explanation of the detection of this
band was that it was the result of the upregulated transcription of the
LDLRΔ4 mRNA. As a result, we performed the IHC experiments to
characterize the location and function of LDLRΔ4 in LDLR-/- mice
compared to the full-length LDLR in NTG mice, as noted in chapter 2. We
communicated these results to Dr. Herz, who was of the opinion that the
LDLR bands in LDLR-/- lanes are the result of non-specific binding of the
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LDLR-/- antibody. Rather than creating an impasse, these opinions show
the necessity of developing an antibody raised against an immunogenic
region specific for LDLRΔ4. We attempted to induce these antibodies in
BALB/c mice and rabbits, but the unique signature of the LDLRΔ4 is
insufficient to generate an immune response, and therefore, our efforts
were not fruitful.

The abovementioned obstacles did not mar our investigations, as
our subsequent data suggested that LDLRΔ4 might play a role in AD
pathogenesis. We found that the transcription level of this LDLR isoform
is increased two-fold in amyloid-ridden PSAPP mice. Because of the ability
of this LDLR species to co-localize with apoE, further work should focus
on identifying the kinetics dictating the interaction between LDLRΔ4 and
apoE. The predicted tertiary structure of the putative apoE-binding region
on LDLRΔ4 strikingly resembled that on the full-length counterpart. Also,
it is possible that LDLRΔ4 may have other ligands, the identification of
which will reveal important information about cholesterol metabolism in
the CNS. Proteomic-based screens could help answer these questions.
However, it will be difficult to make significant progress in this aim until
we can generate antibodies specific to LDLRΔ4.
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There is no direct evidence indicating that serum cholesterol
crosses into the CNS (Dietschy & Turley, 2004). The logical suspicion that
this might be the case is well founded: first, the suckling period, when
dietary cholesterol is introduced to the organism for the first time,
coincides with the highest cholesterol requirement for CNS growth and
myelination (Dietschy & Turley, 2004); second, endothelial cells that
make up the blood-brain barrier express nuclear receptors that regulate
the expression of cholesterol transporters like ABCA1 (ATP-binding
cassette A1) (Ohtsuki, et al., 2004; Panzenboeck, et al., 2002); finally,
mRNA for LDLR is found in the brain (Hofmann, et al., 1987). Together,
these observations support the notion that serum lipoproteins could enter
the CNS. On the contrary, experimental data indicate that the CNS is
largely independent from peripheral cholesterol metabolism. The
availability of a mouse model that favors lipid removal from periphery
selectively from the CNS would be very powerful for characterizing such
differences. Furthermore, the onset of many neurodegenerative diseases
such as vascular dementia, Niemann-Pick’s disorder, and AD are
associated with cholesterol dysregulation. Thus, the LDLR-/- mouse
becomes a powerful tool to study the differences between peripheral and
CNS cholesterol metabolism, for instance, by crossing this mouse with
other models of neurodegenerative diseases and documenting changes in
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the disease outcome. Inherently, LDLRΔ4 may be a key participant of
these processes and would be characterized in subsequent research
efforts.

An important implication of these results is that alternative splicing
must be taken into account when designing knock-out and siRNA
mechanisms. To our knowledge, the only other example of a related
knockout escape by alternative splicing was described for the sorLA/LR11
knock-out mouse during the preparation of this work. The sorLA/LR11
knock-out mouse also undergoes an identical splice-mediated elusion of
the knock-out scheme as we preliminarily reported in the LDLR-/- mice
(Abisambra, et al., 2007; Dodson, et al., 2008). The results also
implicate deletion of exon 4, the site where the new RNA cleavage and
poly-adenylation site was introduced in the sorLA/LR11-/- mouse. At the
mRNA and protein level, the authors found similar results to ours,
implying that this alternative splicing activity may be common in the
LDLR family of proteins. Together, these results support the conclusion
that exon skipping must be considered while targeting an exon for knockout mouse generation. More research to determine the normal function of
splice variants of LDLR and SorLA/LR11 should prove valuable in
determining if these shortened proteins work independently or in concert
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with the cholesterol and apoE metabolism. Furthermore, search for other
splicing motifs within gene families may shed light on unprecedented
regulation of the functions of the products of such gene families. In the
case of LDLR, the exon 4 splice variant may be expressed to eliminate
ligand competition between apoB and apoE. If so, this phenomenon
might be a more efficient pathway for apoE metabolism. Participation of
other LDLR-family members and their splice variants in cholesterol
regulation remains to be determined.

The second focus of my work is presented in chapter 3. Many
studies approached the elucidation of links between LDLR and AD by
modifying the former and documenting changes in the latter. To the
contrary, our strategy was to determine if the impact of APP/Aβ
overexpression would modify LDLR. This perspective would not only
clarify details of apoE metabolism by LDLR, but also do so during APP/Aβpromoted disease.

We identified detrimental effects to microtubule organization by
APP/Aβ overexpression. Due to the critical functions of microtubules
necessary for cell survival, we suspect that the impact of microtubule
damage could participate in pathogenesis of AD. For example, changes in
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cell morphology during disease could be explained by APP/Aβ-induced
damage to microtubules. Therefore, cytoarchitectural support would be
compromised leading to the neuritic atrophy.

Another example of microtubule dysfunction is that protein and
vesicle trafficking could be reduced or inhibited. The implications of
microtubule damage in this scenario would depend on the particular
protein or vesicle being affected at any point in time. In our studies, we
found accumulation of LDLR in the TGN. Furthermore, its localization in
the plasma membrane was significantly reduced, which indirectly may
have led to an attempted compensatory increase in its expression.

Microtubule-mediated dysfunction of the LDLR pathway could have
severe implications for apoE metabolism, and thusly cholesterol
homeostasis. Presumably, depletion of LDLR from the plasma membrane
may lead to decreased import of apoE and its lipid contents (including
cholesterol). This would result in two opposing outcomes that can be
viewed as an acute and chronic cellular adaptation.

Reduced cholesterol import inherently leads to low intracellular
cholesterol levels. Consequently, SREBPs are cleaved from the Golgi
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apparatus and translocate into the nucleus for transcriptional activation of
the cell machinery involved in both de novo cholesterol biosynthesis and
increased production of cholesterol receptors. We find evidence for this
effect with the detection of increased mRNA and LDLR protein levels.
Other reports have suggested that certain regions of AD brains have
increased levels of HMG CoA reductase, the rate-limiting enzyme in the
cholesterol biosynthetic pathway. Together, these data suggest that the
cell has induced transcriptional activation of proteins responsible for
increasing cholesterol production and import. However, other apoE
receptors like LRP-1, apoER2, and VLDLR follow the same transport as
LDLR during low intracellular cholesterol conditions. Therefore, APP/Aβ
destabilization of microtubule dynamics appears to reduce or impedes
apoE receptor transport to the plasma membrane. As a result, the only
cholesterol available for the cell is that which is made de novo within
itself. This single source would increase the time during which the cell
reaches normal cholesterol levels. It would be interesting to see if slower
adaptation to decreases in intracellular cholesterol can cause cellular
stress, lipid peroxidation due to excess lipid concentration on
membranes, or other byproducts that result in cell toxicity. This would be
especially impactful for neurons, whose cholesterol requirement is very
high.
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Also, cholesterol migration to and storage in membranes would
inherently increase its rigidity and the formation of lipid rafts. APP
anchoring within lipid rafts favors the β- and γ- secretase-induced
amyloidogenic pathway, whereas non-raft APP is mainly cleaved by αsecretase. Animals fed high cholesterol diets show an increase in amyloid
plaque formation in rabbits and in transgenic mouse models of AD
(Howland, et al., 1998; Shie, et al., 2002; Sparks, et al., 1994);
moreover, in these mice, the high cholesterol diet induced cognitive
decline (Thirumangalakudi, et al., 2008). In vitro studies showed that
APP processing is highly dependent upon availability of cellular
cholesterol. Cholesterol-depleted rat hippocampal primary neurons show
reduced APP processing into Aβ (Fassbender, et al., 2001; M. Simons, et
al., 1998) yet favor the generation of non-amyloidogenic APP processing
by α-secretase (Bodovitz & Klein, 1996; Kojro, et al., 2001).

Therefore, increased Aβ-production could ensue, further feeding
into deregulation of cholesterol import and production. Chronically, it
would be difficult to predict if the cell, particularly AD neurons, would
have too high or too low cholesterol levels. Nonetheless, it would be safe
to say that cholesterol homeostasis is altered. This may be especially
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detrimental for cells that require high cholesterol levels like neurons.
Furthermore, it may well constitute one of the initial steps of
neurodegeneration in AD.

Other implications for APP/Aβ-mediated microtubule damage may
be the release of tau. As a microtubule stabilizer, tau levels may increase
due to the reduction or disorganization of microtubules. Consequently,
free tau would be available for hyper-phosphorylation and aggregation
into tangles. It is not clear yet whether free tau becomes more hyperphosphorylated than microtubule-bound tau, but the availability of
phosphorylation sites on it are increased while not bound.

Besides abnormal processing, Aβ levels can also be augmented by
increasing production of APP. Since the APP gene resides on chromosome
21, individuals with trisomy 21 (resulting in Down’s Syndrome – DS) are
subject to higher levels of APP, and thusly Aβ. By the fourth decade,
these individuals develop signs of dementia, and their brains are heavily
plaque-ridden. Interestingly, the serum cholesterol and lipid profiles of
these individuals are abnormal, yet they are protected against
atherosclerosis. It would be interesting to assess whether LDLR turnover
rates are changed in different tissues of individuals with trisomy 21.
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Careful follow-up of these patients may reveal knowledge about the in
vivo relationship of LDLR and APP overexpression. These potential studies
could provide insights into the effects and mechanisms by which APP
overexpression modulates of apoE metabolism.

We show increased LDLR in APP transgenic mice and APP overexpressing cells and a decreased LDLR in APP-/- mice. One mechanism
for this appears to be decreased expression of the protein responsible for
LDLR turnover, PCSK9. These observations suggest that, rather than a
precursor, DS and AD dyslipidemia is a consequence of AD-like amyloid
pathology induced by increased APP. The molecular mechanisms
underlying these events remain unclear. The scope of our methods does
not encompass enough data to confirm that these conditions are
generalized to other models of APP over-expression. Further analysis of
tissues and serum lipid profiles from AD patients may reveal important
insights into cholesterol-induced pathogenesis. Regardless, careful
evaluation of the mechanisms underlying APP processing as a factor of
cholesterol levels may yield novel therapeutic targets. In this regard,
PCSK9 inhibitors and activators as a means to manipulate LDLR may
provide modulation of APP processing into Aβ.
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In conclusion, we provide further insight into the complicated
system of cholesterol metabolism in the brain from the perspective of the
LDLR. Furthermore, we do so on the basis of Alzheimer’s, a condition
where altered cholesterol levels have an unknown impact on the disease
pathogenesis and/or progression. Nonetheless, and unexpectedly, our
work culminates in further detailing a link between APP/Aβ and abnormal
microtubule formation.
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APPENDIX A
Activation of the Hepatic LDL Receptor by Thyroid Hormone
This appendix was prepared by Dayami Lopez, Jose F. Abisambra
Socarrás, Mohini Bedi, and Gene C. Ness.

Abstract

The question of whether mature sterol regulatory element binding
protein-2 (SREBP-2) is involved in the transcriptional activation of the
hepatic low density lipoprotein (LDL) receptor by thyroid hormone was
investigated. Western blotting analysis and electrophoretic mobility shift
assays demonstrated that mature (nuclear) SREBP-2 protein could be
detected in the nuclear extracts prepared from normal animals but not in
extracts

prepared

from

thyroparathyroidectomized

either
(Tx)

rats

hypophysectomized
–

two

(Hx)

hypothyroid

or

states.

Treatment of Hx rats with T3 restored LDL receptor mRNA levels in about
1 hr and caused a 6-fold increase 2.5 hrs after T3 administration. No
detectable mature SREBP-2 was seen in this time period despite a
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substantial reduction in serum cholesterol levels caused by T3 treatment.
The data indicate that SREBP-2 is not required for transcriptional
activation of the LDL receptor by thyroid hormone suggesting a direct
effect of this hormone on LDL receptor transcription.
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Introduction

Hypothyroidism, in both humans and experimental animals, is well
known to be accompanied by elevated levels of serum cholesterol,
especially low density lipoprotein (LDL)-cholesterol [1-6]. The effect can
be reversed by thyroid hormone treatment [5-13].

This property of

thyroid hormones has been extensively explored in the development of
thyromimetics as possible anti-cholesterolemic drugs [8,14-16]. Several
studies have established that the effects of thyroid hormone on serum
cholesterol levels are due, at least in part, to alterations in expression of
the hepatic LDL receptor [4, 13, 15, 17-21]. In hypophysectomized rats,
for example, administration of thyroid hormone rapidly and significantly
increases hepatic LDL receptor mRNA and protein levels within 1 hour
[18]. This enhancement in hepatic LDL receptor expression results from
4- to 5-fold increases in the rate of transcription that occurs 30 to 60
minutes after giving thyroid hormone [22]. Based on this, it is logical to
assume that thyroid hormone influences the expression of this gene
through a direct mechanism involving activation of its nuclear receptors
(TRs).
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Independent of any direct effect that thyroid hormone may have via a
TR, the possibility that induction of hepatic LDL receptors occurs as a
consequence of reduction in cellular levels of cholesterol, a key factor in
regulation of the LDL receptor [23-29], cannot be ignored. In the human
LDL receptor gene, transcriptional regulation by cholesterol requires a 10base pair (bp) element, designated sterol response element-1 (SRE-1)
[30]. SRE-1 is located in the center of two Sp1 binding sites [30]. In
vivo, all three elements, the SRE-1 and the two Sp1 sites, are necessary
for high levels of transcription in the absence of sterols [30]. Putative
SRE containing regions have been identified in the promoters of the rat
[31], hamster [31], and mouse [32] LDL receptor genes.

Transcriptional activation through an SRE is mediated by a group of
proteins known as sterol regulatory element binding proteins (SREBP-1a,
-1c and -2) [33-40]. SREBPs are synthesized as 125 kDa precursors that
are attached to the endoplasmic reticulum (ER) membrane and the
nuclear envelope [41, 42].

Maturation of these transcription factors

occurs through a proteolytic process that releases their NH2-terminal
(active) regions, which enter the nucleus, bind to a SRE, and activate
transcription of a target gene [39, 41].
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Sterol regulation of the

proteolytic cleavage resides in the formation of a complex between the
SREBP precursor and another membrane bound protein called the SREBP
cleavage activating protein (SCAP) [43]. Under high cholesterol levels,
the SREBP/SCAP complex is retained in the ER preventing SREBP
processing [43].

Once the ER membrane becomes depleted of

cholesterol, the SREBP/SCAP complex moves to the Golgi complex where
proteolytic cleavage of SREBP occurs [43]. Although in cultured cells, the
three SREBPs appear to act independently and in an apparent redundant
manner [44], in vivo studies clearly indicate that SREBP-1c is involved in
the activation of fatty acid and glucose/insulin metabolism related genes,
whereas SREBP-2 is more specific for genes involved in cholesterol
metabolism such as the LDL receptor [43]. Thus, SREBP-2 could be
considered a potential candidate to mediate thyroid hormone’s effects on
the LDL receptor gene.

Interestingly, increases in mature SREBP-2

protein levels as a result of thyroid hormone treatment have been
recently reported by Shin and Osborne [45]. In that study, changes in
mature SREBP-2 protein levels seen in the presence of thyroid hormone
directly correlated with changes in LDL receptor mRNA levels [45].

In view of these findings, we set out to determine whether an increase
in mature SREBP-2 might precede or occur simultaneously and thus
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might mediate the increase in hepatic LDL receptor expression caused by
thyroid hormone. No detectable mature SREBP-2 was found in the first
2.5 hrs following thyroid hormone administration when hepatic LDL
receptor mRNA was maximally induced. These data indicate that the
rapid transcriptional activation of the rat hepatic LDL receptor by thyroid
hormone is not dependent on mature (nuclear) SREBP-2 protein. This
finding supports a mechanism involving a direct effect of thyroid hormone
on the rat hepatic LDL receptor gene.
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Materials and Methods

Animals.

Normal,

hypophysectomized

(Hx),

and

thyroparathyroidectomized (Tx) male Sprague-Dawley rats weighing 125
to 150 g were purchased from Harlan Industries (Madison, WI).

All

protocols involving animals were approved by the University of South
Florida IACUC Committee. Normal and Hx rats received regular water and
Purina Rodent Laboratory Chow 5001 ad libitum. The Tx animals were
maintained on 2% (w/v) calcium gluconate as their drinking water and an
iodine-deficient diet (Harlan Industries). All animals were housed in a
light-controlled reversed cycle room with 12 hrs of light followed by 12
hrs of darkness. Hx and Tx rats were used in experiments 10 to 21 days
following surgery. The status of the Hx rats was confirmed by failure to
gain weight, whereas the status of the Tx rats was confirmed by weight
gains of one-half the rate of normal rats. Some rats received an injection
of triiodothyronine (T3; Sigma Co., St. Louis, MO) subcutaneously at a
dose of 10 µg per 100 g of body weight, 1 to 2.5 hours before
euthanatization. Rats were euthanatized at the fourth hour of the dark
period by an isofluorane overdose. Liver portions were quickly removed
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for preparation of nuclear extracts and RNA.

Serum samples were

prepared from all the rats. Free-T3 levels in the serum of these animals
were determined using an ELISA kit from Research Diagnostics, Inc.
(Flanders, NJ). Serum cholesterol levels were determined using Infinity
Reagent from Sigma Co., (St. Louis, Mo).

Materials. The BCA protein assay kit, pre-cast 4-20% sodium dodecyl
sulfate-polyacrylamide gels (SDS-PAGE), and the SuperSignal ULTRA
Chemiluminescent Substrate were purchased from Pierce (Rockford, IL).
Pre-stained protein molecular weight markers and SYBR Green Real-time
PCR supermix were obtained from BioRad Labs (Hercules, CA).
Nitrocellulose membrane and BioMax-MR films were purchased from
Fisher Scientific (Norcross, GA). Antibody specific for SREBP-2 and the
horseradish peroxidase-conjugated goat-anti-rabbit secondary antibody
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The
free-T3 ELISA kit was from Research Diagnostics, Inc. (Flanders, NJ).
TRβ1 specific antisera was purchased from Upstate Biotechnology Inc.
(Lake Placid, NY). Oligonucleotides were synthesized by Integrated DNA
Technologies (Coralville, IA). Klenow enzyme, restriction enzymes, and
the Reverse Transcriptase System were purchased from Promega Corp
(Madison, WI). [α32P]dCTP (3000 Ci/mmol) was obtained from Perkin
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Elmer/New England Nuclear (Wilmington, DE). TRI Reagent was obtained
from Molecular Research Center (Cincinnati, OH). The Turbo DNA-free
Kit was purchased from Ambion. All other chemicals were obtained from
Fisher Scientific or Sigma Chemical Co. (St. Louis, MO).

Preparation of nuclear extracts.

Rat liver samples, 400 mg, were

minced and homogenized in 10 ml of buffer A (15 mM Tris-HCl, pH 7.5;
15 mM KCl, 15 mM β-mercaptoethanol, 2 mM EDTA, 0.5 mM EGTA, 0.15
mM spermine, 0.5 mM spermidine, 1.9 M sucrose, 0.1% Triton X-100 and
0.1 mM PMSF) using a motor-driven serrated Teflon pestle in a 20 ml
glass Potter-Elvehjem homogenizer.

The homogenate was filtered

through nylon gauze and layered over an equal volume of the same
buffer lacking Triton X-100. Samples were centrifuged at 90,000 x g for
90 minutes at 4°C. The white nuclei pellet was resuspended in 1 ml of
buffer B (15 mM Tris-HCl, pH 7.5; 15 mM NaCl, 60 mM KCl, 15 mM βmercaptoethanol, 0.15 mM spermine, 0.5 mM spermidine, 0.34 M sucrose
and 0.1 mM PMSF) and centrifuged at 3,000 x g for 5 minutes at 4°C.
The resulting pellet was resuspended in 1 ml of Buffer C (420 mM NaCl,
20 mM HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 1 mM
Na3VO4, 1 mM Na4P2O7, 1 mM DTT and 0.5 mM PMSF) and incubated at
4°C for 30 minutes on a rotating wheel to extract nuclear protein. The
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mixture was then centrifuged for 15 minutes at 8,400 x g. Supernatants
corresponding to the nuclear extracts were aliquoted and stored at -70°C
until used.

Protein concentrations were determined using the BCA

protein assay kit (Pierce).

Western blotting analysis.

Ten µg of liver nuclear protein were

denatured at 100oC in loading buffer and subjected to electrophoresis on
a pre-cast 4-20% SDS-PAGE.

Pre-stained molecular weight markers

(Bio-Rad Labs) were applied to one lane. After electrophoresis, samples
were electroblotted onto nitrocellulose membranes (0.2 µm pore) in
buffer containing 0.25 M Tris hydrochloride (Tris-HCl; pH 8.3), 1.92 M
glycine, and 20% (v/v) methanol for 16 hours at 4oC. To verify equal
protein loading, membranes were stained with 0.1% (v/v) Ponceau
Solution in 5% (v/v) acetic acid (Sigma Co.) and destained in water.
Blocking was performed in 5% (w/v) non-fat dry milk in TTBS (10 mM
Tris-HCl pH 8.0, 150 mM NaCl, 0.01% Tween-20) for 30 min at room
temperature. Western blotting analysis for SREBP-2 and TRβ1 (control)
proteins was carried out with a 1:1000 of rabbit polyclonal antibodies to
SREBP-2 and TRβ1, respectively, in TTBS supplemented with 2% (w/v)
non-fat dry milk and incubated overnight at 4oC.

Immunoreactive

proteins were then visualized using a 1:10,000 dilution of horseradish
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peroxidase-conjugated

goat

anti-rabbit

antisera

(Santa

Cruz

Biotechnology) in TTBS supplemented with 2% (w/v) non-fat dry milk
and the SuperSignal ULTRA Chemiluminescent Substrate method
(Pierce). Washes after each antibody (six total) were performed with
TTBS supplemented with 0.5% (w/v) non-fat dry milk.

Multiple

exposures ranging from 5 seconds to 20 minutes were made.

Electrophoretic mobility shift assays. Electrophoretic mobility shift
assays were performed as previously described [46] except that binding
reactions were carried out at room temperature for 30 minutes.
Complementary oligonucleotides containing the rat LDL receptor SRE
motif located at bp -242 to -234 were synthesized and labeled using
[α32P]

dCTP

and

the

Klenow

polymerase

fill-in

reaction

with

oligonucleotide pairs constructed to provide overhangs. The sequence of
one strand of the complementary oligonucleotide probe was 5’TTTTTGAAAATCACCCCACTGCAGACTCCT-3’.

Binding reactions were

carried out in 20 µl volumes with the indicated proteins and 25 fmol of
labeled probe. SREBP-2 specific antibody was added as indicated. The
samples were run on 6% acrylamide/bisacrylamide gels. Gels were then
vacuum-dried and exposed to X-ray films at -80oC for 12-24 hours.

278

Real-time Reverse-transcriptase PCR. Total hepatic RNA was isolated
using the guanidinium thiocyanate-phenol-chloroform extraction method
employing TRI Reagent (Molecular Research Center).

This method

consistently yields 5-8 µg of RNA per mg of tissue. Fifty µg of total RNA
was first DNase I treated using the Turbo DNA-free kit (Ambion). After
inactivation of the DNase I enzyme, 1 µg of the DNA-free RNA was
reverse transcribed using Promega’s Reverse transcriptase system and
random primers as per the manufacturer’s instructions. Real-time PCR
reactions were performed using 100 ng of ssDNA, the BioRad SYBR Green
real-time RT-PCR kit, and the iCycler real-time PCR system. Rat LDL
receptor specific primers used were 5’-GGGCTGGCGGTAGACTGGATC-3’
(sense) and 5’-CAATCTGTCCAGTACATGAAGC-3’ (antisense). The size of
the LDL receptor fragment that is amplified using these primers is 200
bp. Primers specific for 18S (5’-GTAACCCGTTGAACCCCATT-3’ and 5’CCATCCAATCGGTAGTAGCG-3’) were used as the internal control for
these studies. The parameters for the PCR reactions were denaturation
at 95°C for 3 minutes, followed by 39 cycles of denaturation at 95°C for
30 seconds, annealing at 63°C for 30 seconds, and extension at 72°C for
30 seconds.

The melt curve was performed starting at 55oC with

increases of 0.5oC every 30 seconds for 80 repeats ending at 95oC.
Quantitation of the results was performed using the Comparative CT
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method.
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Results and Discussion

To examine whether levels of mature (nuclear) SREBP-2 protein in
liver correlate with serum levels of thyroid hormone, liver nuclear
extracts

and

serum

samples

were

prepared

from

normal,

hypophysectomized (Hx) and thyroparathyroidectomized (Tx) rats.
Western blotting analysis for mature SREBP-2 protein and measurements
of free-T3 levels in the serum were performed as described in Material
and methods.

As shown in Fig. 1, SREBP-2 protein was detected in

nuclear extracts prepared from normal animals but not in nuclear
extracts prepared from either Hx or Tx rats. Free-T3 levels for the normal
and Hx rats were 4.35 and 1.75 pg/dl, respectively, whereas Tx rats’
free-T3 levels were too low to be determined (Fig. 1). Changes in SREBP2 levels appear to be specific for this protein, since control Western blots
obtained using a thyroid hormone receptor β1 (TRβ1) specific antibody
demonstrated that TRβ1 levels were unaffected under the same
conditions (Fig. 1).

To further assess the presence of mature SREBP-2 protein in the
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normal, Hx and Tx nuclear extracts, electrophoretic mobility shift assays
were carried out using the rat LDL receptor SRE motif located at bp -242
within the promoter region of this gene (GenBank accession number
AY675581). As shown in Fig. 2A, formation of a DNA/protein complex
between liver nuclear extracts and the SRE probe was observed in the
presence of extracts from normal (N; lanes 2-4) but not from Tx (lanes
5-8) or Hx (lanes 9-11) rats. Although these results are in complete
agreement with the Western blot data presented in Fig. 1, it was still
necessary to determine whether SREBP-2 was part of the DNA-protein
complex observed using the normal samples.

To examine this,

electrophoretic mobility shift assays were performed in the presence of a
SREBP-2 specific antibody. As shown in Fig. 2B (lane 4), the addition of
SREBP-2 antibody (5 µg IgG) to the binding reactions was able to reduce
DNA-protein complex formation between normal liver nuclear extracts
and the rat LDL receptor SRE motif. Once again, no binding between Tx
nuclear extracts and the SRE motif was observed (Fig. 2B, lanes 3 and
5).

Participation of SREBP-2 in the thyroid hormone-dependent regulation
of the LDL receptor gene was originally suggested by Shin and Osborne
[45].

In that report, it was demonstrated that the SREBP-2 gene is
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regulated by thyroid hormone mainly at the transcriptional level via
binding and activation of a putative DR-4 TRE site located in the SREBP-2
promoter [45]. This resulted in increases in mature SREBP-2 protein
levels with comparable increases in LDL receptor mRNA [45]. However,
considering the rapid time course (30 to 60 minutes) for the T3-mediated
activation of LDL receptor transcription [22], it is logical to assume that if
SREBP-2 is responsible for the changes seen in hepatic LDL receptor
expression under these conditions, an increase in mature SREBP-2
protein levels should precede or occur simultaneously with the
enhancement in LDL receptor transcription. To examine this possibility,
Hx rats were injected subcutaneously with 10 µg of T3 per 100 g of body
weight, 1 to 2.5 hours before euthanatization. Hepatic nuclear extract
preparation and Western blotting analysis for mature SREBP-2 protein
were performed as described in Fig. 1. Surprisingly, no mature SREBP-2
protein was detected in any of the nuclear extracts prepared from the Hx
animals even at 2.5 hours after T3 injection (Fig. 3).

Hepatic LDL

receptor mRNA levels were returned to near normal 1 hr after T3
administration. At 2.5 hrs after T3 treatment hepatic LDL receptor mRNA
levels were increased 6-fold over those of the Hx animals (Fig. 3).
Serum cholesterol levels were substantially decreased by T3 treatment to
levels below those of the normal (Fig. 3). This data clearly indicates that
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SREBP-2 is not required for transcriptional activation of the hepatic LDL
receptor after thyroid hormone treatment. In the studies by Shin and
Osborne [45] hypothyroid mice were treated daily for 4 days with 100 µg
of T3 per 100 g of body weight. This dose of T3 is much higher than that
used in the present study. In the previously reported study [45] any
rapid effect of thyroid hormone on hepatic LDL receptor mRNA would
have been overlooked.

It is well established that T3 acts to quickly

increase transcription of the hepatic LDL receptor gene [4, 18, 22].
The data presented in this report demonstrate that mature SREBP-2 is
not required for transcriptional activation of the rat LDL receptor by
thyroid hormone.

These findings support a mechanism involving a

primary effect of thyroid hormone on the LDL receptor gene via activation
of the TRs. In fact, we have identified two promoter regions located at 614 and -156, relative to the translation start site, that specifically bind to
recombinant TRβ1 (unpublished observations). Furthermore, studies using
the human gene have suggested the presence of functional TREs between
–687 and –160 bp upstream of the ATG translation start site [51].
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Figures

Fig. 1.

Effects of hypophysectomy and thyroparathyroidectomy on

mature sterol regulatory element binding protein-2 (SREBP-2) levels in
rat

liver.

Liver

nuclear

extracts,

10

µg

each,

from

normal,

hypophysectomized (Hx), and thyroparathyroidectomized (Tx) rats were
subjected to Western blotting analysis for mature SREBP-2 protein. FreeT3 levels in serum samples were determined as described under Materials
and methods. “UD” refers to T3 levels too low to be determined. The
blots were also probed with TRβ1 specific antibody. Molecular weight
markers were applied to one lane.

A representative Western blot is

presented. Similar results were obtained in four separate experiments.
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Fig. 2. Electrophoretic mobility shift assays depicting binding of rat liver
nuclear extracts to the rat LDL receptor SRE motif.

32

P-labeled rat LDL

receptor SRE (Rat LDLR SRE) probe was incubated with 10 µg of the
indicated liver nuclear extract as described in Materials and methods.
Representative electrophoretic mobility shift assay autoradiographs are
shown. “P” refers to a binding reaction performed in the presence of
probe only.

The position of the SRE/protein complex in each

autoradiograph has been indicated by an arrow. A. Binding of normal
(N)

but

not

of

the

thyroparathyroidectomized

hypophysectomized (Hx) extracts to the SRE.

B.

(Tx)

and

SREBP-2 specific

antibody (5 µg IgG) reduces the complex formation between the normal
liver nuclear extracts (N) and the rat LDL receptor SRE.
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Fig. 3. Effects of triiodothyronine (T3) treatment on mature SREBP-2
protein and LDL receptor mRNA levels in rat liver. Liver nuclear extracts
and total RNA from normal and Hx rats treated with T3 for the indicated
times were analyzed by Western blotting analysis and real-time RT-PCR
for mature SREBP-2 and LDL receptor mRNA respectively.

A

representative Western blot is presented. Similar results were obtained
in three separate experiments. The data from the real-time RT-PCR are
represented as mean relative LDL receptor mRNA levels where the value
of LDL receptor mRNA for the normal sample was set to 1.0. Serum
levels of free-T3 are presented in terms of pg/dl.
values in mg/dl for each rat are also presented.
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APPENDIX
LDLRΔ4 cDNA Sequence

>LDLR_K-O_LIVER+ANTI-SENSE
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTGTCC
ATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTCCAC
AGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCTGGG
GACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACACCCA
CTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACTCGTTCCTGCT
GCATGAGTCTTCTA
300

>LDLR_K-O_LIVER+SENSE
GGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGCAGCCCCGAGT
GCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCATGTCTGTCACC
TGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCAGCCGATGCAT
TCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGTGAAAATGACT
CAGACGAACAAGGCTGTCCGGTGGCCACCTGCCGACCTGATGAATTC
CAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCCAGTGTGACCG
TGAACATGACTGCAAGGACATGAGCGACGAGCTCGGCTGCGTCAATG
TGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTCACAGTGGGGAG
TGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCGCGACTGCCAGGA
CTGGTCGGATGAGCCCATCAAGGAGTGCAAGACCAACGAGTGTTTGG
ACAACAATGGTGGCTGTTCCCACATCTGCAAGGACCTCAAGATTGGC
TCTGAGTGCCTGTA

>NORMAL-LIVER+ANTI-SENSE
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
301

TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGCGCAGTGCTCCTCATCTGACTTGTCCTTGCAGTCTGCCTCGCC
GTCACAGACCCAGCTGCGATGGATACACTCACTGCTACCACAGTGGA
ACTCCAGGGAGGAGCAGGGGCTGCTAACGCCTTTGGAGGCCGTGTC
TCGGCCCTGGCAGTTCTGTGGCCACTCATCGGAGCCGTCAACACAGT
CGACATCCCCGTCGCAGGCCCAAAGACTGGGGATGCATATGGATGAG
TTGCAGCGGAAGTGGGCGGGGCCACAAGTGGTGGCCTGGCAGTGGG
CCTCATCAGAGCCATCTAGGCAATCTCGGTCTCCATCACACACAAACT
GCGGGGAGATGCACTTGCCATCCTGGCATCGGAAGTCATCCTGGGA
GCACGTCTTGGGGGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGT
CTACCTGTCCATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACA
CGGCCTCCACAGCTGAATTGATTGGACTGACAGGTGACAGACATGCA
TGTCTCTGGGGACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCAT
CGCACACCCACTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACT
CGTTCCTGCTGCATGAGTCTTCTA
302

>NORMAL-LIVER+SENSE
GGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGCAGCCCCGAGT
GCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCATGTCTGTCACC
TGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCAGCCGATGCAT
TCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGTGAAAATGACT
CAGACGAACAAGGCTGTCCCCCCAAGACGTGCTCCCAGGATGACTTC
CGATGCCAGGATGGCAAGTGCATCTCCCCGCAGTTTGTGTGTGATGG
AGACCGAGATTGCCTAGATGGCTCTGATGAGGCCCACTGCCAGGCCA
CCACTTGTGGCCCCGCCCACTTCCGCTGCAACTCATCCATATGCATCC
CCAGTCTTTGGGCCTGCGACGGGGATGTCGACTGTGTTGACGGCTCC
GATGAGTGGCCACAGAACTGCCAGGGCCGAGACACGGCCTCCAAAG
GCGTTAGCAGCCCCTGCTCCTCCCTGGAGTTCCACTGTGGTAGCAGT
GAGTGTATCCATCGCAGCTGGGTCTGTGACGGCGAGGCAGACTGCA
AGGACAAGTCAGATGAGGAGCACTGCGCGGTGGCCACCTGCCGACC
TGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCC
AGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACGAGCTCGG
CTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTC
303

ACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCG
CGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGCAAGACC
AACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACATCTGCAAGGA
CCTCAAGATTGGCTCTGAG

>NORMAL-HC+SENSE

GCAGCTGAGAGGAATGCATCGCTAGCAGTGGGTGTGCGATGGCAGC
CCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCATGTC
TGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCAGCC
GATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGTGAA
AATGACTCAGACGAACAAGGCTGTCCCCCCAAGACGTGCTCCCAGGA
TGACTTCCGATGCCAGGATGGCAAGTGCATCTCCCCGCAGTTTGTGT
GTGATGGAGACCGAGATTGCCTAGATGGCTCTGATGAGGCCCACTGC
CAGGCCACCACTTGTGGCCCCGCCCACTTCCGCTGCAACTCATCCAT
ATGCATCCCCAGTCTTTGGGCCTGCGACGGGGATGTCGACTGTGTTG
ACGGCTCCGATGAGTGGCCACAGAACTGCCAGGGCCGAGACACGGC
304

CTCCAAAGGCGTTAGCAGCCCCTGCTCCTCCCTGGAGTTCCACTGTG
GTAGCAGTGAGTGTATCCATCGCAGCTGGGTCTGTGACGGCGAGGC
AGACTGCAAGGACAAGTCAGATGAGGAGCACTGCGCGGTGGCCACC
TGCCGACCTGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGG
TAGCCGCCAGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACG
AGCTCGGCTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTC
AAGTGTCACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTC
CGCCCGCGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGC
AAGGACCAACGAGTGTTTGCGACAACAATTGGTGGCTGTTCCCACAT
CTGCAAGGACCCGCAGATTTGGCTCTGGAGTTGCCTGGTAAAA

>NORMAL-HC+ANTI-SENSE
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
305

CACCGCGCAGTGCTCCTCATCTGACTTGTCCTTGCAGTCTGCCTCGCC
GTCACAGACCCAGCTGCGATGGATACACTCACTGCTACCACAGTGGA
ACTCCAGGGAGGAGCAGGGGCTGCTAACGCCTTTGGAGGCCGTGTC
TCGGCCCTGGCAGTTCTGTGGCCACTCATCGGAGCCGTCAACACAGT
CGACATCCCCGTCGCAGGCCCAAAGACTGGGGATGCATATGGATGAG
TTGCAGCGGAAGTGGGCGGGGCCACAAGTGGTGGCCTGGCAGTGGG
CCTCATCAGAGCCATCTAGGCAATCTCGGTCTCCATCACACACAAACT
GCGGGGAGATGCACTTGCCATCCTGGCATCGGAAGTCATCCTGGGA
GCACGTCTTGGGGGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGT
CTACCTGTCCATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACA
CGGCCTCCACAGCTGAATTGATTGGACTGACAGGTGACAGACATGCA
TGTCTCTGGGGACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCAT
CGCACACCCACTTGCTAGCGATGCATTTTCCGTCTCTACACTGGGAAC
TCGTTCCTGCTGCATGGAGTCTTCT

>NORMAL-CORTEX+ANTI-SENSE
ACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCACTCCTTGAT
GGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTCGCACACC
306

TTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTTGTTGGGG
CCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGCTCATGTC
CTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGAATGCAGG
AGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGCCACCGCG
CAGTGCTCCTCATCTGACTTGTCCTTGCAGTCTGCCTCGCCGTCACAG
ACCCAGCTGCGATGGATACACTCACTGCTACCACAGTGGAACTCCAG
GGAGGAGCAGGGGCTGCTAACGCCTTTGGAGGCCGTGTCTCGGCCC
TGGCAGTTCTGTGGCCACTCATCGGAGCCGTCAACACAGTCGACATC
CCCGTCGCAGGCCCAAAGACTGGGGATGCATATGGATGAGTTGCAG
CGGAAGTGGGCGGGGCCACAAGTGGTGGCCTGGCAGTGGGCCTCAT
CAGAGCCATCTAGGCAATCTCGGTCTCCATCACACACAAACTGCGGG
GAGATGCACTTGCCATCCTGGCATCGGAAGTCATCCTGGGAGCACGT
CTTGGGGGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTG
TCCATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTC
CACAGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCT
GGGGACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACA
CCCACTTGCTAGCGATGCATTTTCCGTCTCTACACTGGGAACTCGTTC
CTGCTGCATGGAGGTCTTCTCG

307

>NORMAL-CORTEX+ SENSE
GTGTAGAGACGGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGC
AGCCCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCAT
GTCTGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCA
GCCGATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGT
GAAAATGACTCAGACGAACAAGGCTGTCCCCCCAAGACGTGCTCCCA
GGATGACTTCCGATGCCAGGATGGCAAGTGCATCTCCCCGCAGTTTG
TGTGTGATGGAGACCGAGATTGCCTAGATGGCTCTGATGAGGCCCAC
TGCCAGGCCACCACTTGTGGCCCCGCCCACTTCCGCTGCAACTCATC
CATATGCATCCCCAGTCTTTGGGCCTGCGACGGGGATGTCGACTGTG
TTGACGGCTCCGATGAGTGGCCACAGAACTGCCAGGGCCGAGACAC
GGCCTCCAAAGGCGTTAGCAGCCCCTGCTCCTCCCTGGAGTTCCACT
GTGGTAGCAGTGAGTGTATCCATCGCAGCTGGGTCTGTGACGGCGA
GGCAGACTGCAAGGACAAGTCAGATGAGGAGCACTGCGCGGTGGCC
ACCTGCCGACCTGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCA
CGGTAGCCGCCAGTGTGACCGTGAACATGACTGCAAGGACATGAGC
GACGAGCTCGGCTGCGTCAATGTGACACAGTGTGATGGCCCCAACAA
GTTCAAGTGTCACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCG
ACTCCGCCCGCGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGA
308

GTGCAAGACCAACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACA
TCTGCAAGGACCTCAAGATTGGCTCTGAGTGCCT

>LDLR_K-O-CORTEX+ANTI-SENSE
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTGTCC
ATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTCCAC
AGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCTGGG
GACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACACCCA
CTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACTCGTTCCTGCT
GCATGAGTCTTCT
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>LDLR_K-O-CORTEX+ SENSE

GTGTAGAGACGGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGC
AGCCCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCAT
GTCTGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCA
GCCGATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGT
GAAAATGACTCAGACGAACAAGGCTGTCCGGTGGCCACCTGCCGACC
TGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCC
AGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACGAGCTCGG
CTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTC
ACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCG
CGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGCAAGACC
AACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACATCTGCAAGGA
CCTCAAGATTGGCTCTGAGTGCCTGT

>LDLR_K-O--HC+ANTI-SENSE
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
310

TCCTTGATGGGCTCATCCAACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTGTCC
ATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTCCAC
AGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCTGGG
GACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACACCCA
CTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACTCGTTCCTGCT
GCATGAAGTCTTCT
>LDLR_K-O--HC+ SENSE

GTGTAGAGACGGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGC
AGCCCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCAT
GTCTGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCA
GCCGATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGT
GAAAATGACTCAGACGAACAAGGCTGTCCGGTGGCCACCTGCCGACC
311

TGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCC
AGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACGAGCTCGG
CTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTC
ACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCG
CGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGCAAGACC
AACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACATCTGCAAGGA
CCTCAAGATTGGCTCTGAGTGCCTGT
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